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Surface Interleukin-1 Alpha 
 Interleukin-1α (IL-1α) is a potent cytokine involved in a range of diseases and can be 
found expressed on the cell surface (csIL-1α) and in the soluble form, signalling through the 
type I IL-1 receptor (IL-1R1). IL-1 signalling leads to increased secretion of cytokines, 
recruitment of immune cells thus perpetuating a highly inflammatory environment. It has been 
the understanding for years that IL-1R1 is present on many cell types including macrophages 
and monocytes. We report that there can be false positive staining of target proteins if a 
permeability stain is not introduced. Thus, we show that when gated on intact cells, there is no 
IL-1R1 expressed on macrophages or dendritic cells, and when IL-1R1 is overexpressed, IL-1 
signalling can occur. We also suggest that the mere presence of IL-1R1 is not sufficient to lead 
to IL-1 signalling, but that there is a minimum threshold of IL-1R1 expression for that to occur, 
illustrating a novel checkpoint mechanism to prevent aberrant IL-1 signalling. 
 In the second part of this project, we investigated the nature of csIL-1α, reported to be 
crucial for the senescence-associated secretory phenotype (SASP). We show that pro-IL-1α is 
synthesised de novo and trafficked to the membrane following TLR4 stimulation. We report 
two novel ways by which csIL-1α can be bound, through the type II IL-1 receptor (IL-1R2) 
and glycosylphosphatidylinositol (GPI) anchors. IL-1R2 is responsible for majority of the 
csIL-1α binding to the cell membrane with a small portion of csIL-1α being tethered to a GPI-
associated protein. We report that csIL-1α is significantly downregulated by IFNγ treatment 
but intracellular and secreted IL-1α levels are not affected by this.  
 In conclusion, this thesis has contributed to a better understanding of IL-1 signalling 
through IL-1R1 and its regulation. It has also enhanced the understanding of csIL-1α binding 
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1. General Introduction 
1.1. Introduction to immunity 
The human body is constantly being exposed to millions of microbes every day and the 
immune system is a defence mechanism in organisms that protects the body from disease by 
destroying foreign pathogens and removing harmful molecules produced. Inflammation, a 
localised reaction to injury, elicits a response from the immune system to resolve the infection. 
Immunity can be broken down into innate and adaptive components, which arise at different times 
during an immune response and involve a range of different cell types. Evolution over time due to 
selective pressure of infection, producing a system that has germline-encoded receptors to non-
specifically recognise microbes and lead to their neutralisation and removal is a branch of 
immunity that we now term the innate immune system (Medzhitov et al., 1997). Adaptive 
immunity is the immune response elicited by an antigen to generate antibodies and responses that 
are specific to that antigen. Both arms of the immune system work together to eliminate infection, 
resolve inflammation and retain memory of the infection in order to produce a stronger, more 
efficacious response upon reinfection. 
1.2. Innate immunity: the mighty first responders 
Innate immunity is the first barrier of resistance that pathogens encounter, and it acts within 
minutes of microbe detection persisting for days after exposure. It depends on the recognition of 
conserved characteristics on foreign microbes by phagocytes, which can engulf the pathogen and 
produce a broad and quick response to invading pathogens and limit the damage caused by them. 
Macrophages and neutrophils are key players in phagocytosis. Macrophages are long-lived cells 
that can patrol tissues for invading pathogen and be activated, leading to the recruitment of 
neutrophils to the site of infection. Macrophages and neutrophils are amongst the first immune 
cells to arrive and start an inflammatory response to lead to further recruitment of immune cells. 
Phagocytosis of microbes leads to the fusion of the phagosome with lysosomes within the 
cytoplasm of the phagocyte to cause the degradation of the pathogenic material. In addition, 
phagocytes contain NADPH oxidase (NOX) that can generate reactive oxygen species (ROS) 
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rapidly, leading to cellular damage and subsequent oxidative stress (Panday et al., 2015; Segal, 
2008). There tends to be high neutrophil cell death as a result of this response to infection and dead 
neutrophils are a major part of the pus formed in wounds (Bratton et al., 2011).  
Other important cell types of the immune system include dendritic cells (DCs), eosinophils, 
basophils and natural killer (NK) cells. DCs, like macrophages, also carry out immunosurveillance. 
DCs express antigen receptors, phagocytose pathogen and cause the activation of T cells to bring 
about an adaptive immune response (Clark et al., 2000). Eosinophils are granulocytes that have 
the capacity to store cytotoxic eosinophil peroxidase and the eosinophil major basic protein 
(MBP), which are released upon stimulation. They also express enzymes that are important for 
cell migration and can activate the complement cascade (Shamri et al., 2011). The complement 
system is a series of proteins that are amplified sequentially to lead to the rupture of bacterial cell 
wall, inflammation and phagocytosis (Murphy et al., 2017). Another innate immune cell type, 
basophils, are large granulocytes containing heparin and histamine and they are involved in 
parasitic infections (Voehringer, 2009). 
NK cells are cytotoxic granular lymphocytes that are also part of the innate immune system 
and these contain perforin and granzymes to make pores in the target cell, causing apoptosis 
(Topham et al., 2009). NK cells target tumour cells and cells infected by viruses and along with 
cytotoxic T cells, an immune response is mounted against viruses and tumours thereby tying the 
innate and adaptive arms of immunity together (Topham et al., 2009). Interferons (IFNs) and 
macrophage-secreted cytokines such as Interleukin (IL)-15, IL-18 and IL-12 can induce NK cell 
activation. T cells also produce IL-2, which leads to NK cells proliferation and effector function 
(Pallmer et al., 2016; Vivier et al., 2008). In addition, NK cells have effects on both CD4+ and 
CD8+ T cells to inhibit or promote their activity by the production of cytokines and limiting antigen 
presentation by antigen-presenting cells (APCs) to T cells (Crome et al., 2013). 
Innate immunity relies on pattern recognition receptors (PRRs) expressed on phagocytes 
that recognise pathogen-associated molecular patterns (PAMPs) such as viral coat proteins and 
flagellin from bacteria (Medzhitov et al., 1997). PRRs include toll-like receptors (TLRs), RIG-I-
like receptors (RLRs) and NOD-like receptors (NLRs). TLRs are a class of receptors that have 
been well-studied and are characterized by a ligand-binding domain made up of leucine-rich repeat 
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(LRR) motifs and a signalling domain called the Toll/Interleukin-1 receptor homology (TIR) 
domain (O’Neill et al., 2007). TLRs can be expressed on the cell membrane or intracellularly in 
endosomes in macrophages and DCs (Akira et al., 2006). TLRs recognise an array of PAMPs 
detailed in Table 1 and TLR activation leads to upregulation of pro-inflammatory cytokines, co-
stimulatory molecules and activation of APCs, which present antigenic peptides to members of the 
adaptive immune system. 
 
1.3. Adaptive immunity: long-lasting protection 
Contrary to the first line of defence that is the non-specific innate immune response, the 
adaptive immune response is highly specific to the microbial stimuli and more sophisticated, 
resulting in long-lasting, sometimes life-time, protection (Alberts et al., 2002). The adaptive 
immune response is perpetuated by lymphocytes including T and B cells. T cells arise from the 
bone marrow and develop in the thymus, whereas B cells arise from and develop in the bone 
marrow.  
The adaptive immune system relies on T cell receptors (TCRs) and B cell receptors 
(BCRs). Progenitor T cells give rise to naïve CD4+ and CD8+ T cells that have TCRs, which 
TLR Location expressed Microbial ligand Origin of ligand  
1/2  Cell membrane Triacyl lipopeptides Bacteria 
















3 Cell membrane/endosomes dsRNA Viruses 




5 Cell membrane Flagellin Flagellated bacteria 
7 Endosomes ssRNA RNA viruses 
8 Endosomes ssRNA RNA viruses 
9 Endosomes CpG DNA Viruses, bacteria, protozoa 
Table 1: Location, ligands and origins of ligands for TLRs. Adapted from (Mogensen, 2009). 
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recognise peptide-major histocompatibility complexes (MHC) presented on APCs, thus leading to 
T cell activation (den Haan et al., 2014). CD4 and CD8 are co-receptor surface proteins found on 
T cells to enable binding to MHC II and I respectively, leading to IL-2 secretion by T cells. CD4+ 
T cells are known as T helper cells and they contribute to the adaptive immune response through 
the secretion of cytokines such as IFNγ and IL-2, leading to the induction or inhibition of immune 
responses by CD8+ T cells. This activity can subsequently cause antibody class switching in B 
cells and increase activity of macrophages (Zhu et al., 2008). CD8+ T cells are also known as 
cytotoxic T cells and they function to kill infected cells or tumour cells. CD8+ T cells can be 
induced to release perforin, granulysin and granzymes to lead to apoptosis of the target cells, 
similar to the action of NK cells (Dotiwala et al., 2016). Another CD4+ T cell subset, T regulatory 
cells (Tregs) function to prevent autoimmune diseases and they do this by maintaining tolerance 
to self-antigens and suppress effector T cell function (Corthay, 2009). 
When B cells encounter antigen, they differentiate into effector cells and produce 
antibodies. These antibodies circulate in blood and bind to the antigen that was specifically 
responsible for their production, leading to inactivation of the pathogen by preventing their binding 
to other cells whilst also labelling the pathogen for phagocytosis (Alberts et al., 2002). Progenitor 
B cells can also differentiate into memory B cells to produce an improved response to subsequent 
reinfection with quicker and more efficient generation of antibodies that have higher affinity to the 
pathogen compared to the primary infection (Kurosaki et al., 2015). Orchestrating the 
inflammatory cascade requires immune cells to ‘converse’ with each other, which occurs via the 
release of cytokines and chemokines, resulting in the clearance of the invading pathogen.   
1.4. Inflammation  
An inflammatory response arises when the immune system senses microorganisms that 
bypass the physical barriers of the body, which are the surface epithelia and mucous membranes, 
leading to an influx of leukocytes that signal via soluble factors to recruit more cells. Pain, 
swelling, redness and heat are the hallmarks of inflammation. When there is an infection, cells of 
the innate immune system are recruited to phagocytose the invading pathogen whilst also 
producing a large amount of inflammatory cytokines and chemokines. This recruits other innate 
immune cells and causes cytotoxicity to kill infected cells. The adaptive immune system is then 
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induced, leading to antibody production and T cell effector functions. After clearance of the 
invading microbe, the host retains memory of the infection via memory B cells to allow for a more 
efficient response the next time the same pathogen is encountered. 
Acute inflammation can occur within minutes to hours of trauma and the result of this 
response is controlled by the balance of pro- and anti-inflammatory factors released. Cytokines 
involved in acute inflammation include IL-1, TNFα, IL-6, IL-8 and IL-11 (Feghali et al., 1997). In 
an acute inflammatory setting, recruited neutrophils decrease in number after 4 hours whereas 
mononuclear cells are retained for typically 18 to 24 hours (Ryan et al., 1977). The hallmarks of 
acute inflammation include increased blood flow and permeability of the vasculature, immune cell 
recruitment and raised cytokine levels (Feghali et al., 1997). Acute inflammation is a short-term 
phenomenon and aberrant inflammation is a major underlying factor that mediates the 
pathogenesis of a number of diseases from their initiation to progression into long-term disease.  
Chronic inflammation, on the other hand, occurs in a persistent background state and is 
involved in numerous diseases such as diabetes, asthma, psoriasis, rheumatoid arthritis (RA), 
inflammatory bowel disease (IBD), cancer and atherosclerosis (Barnes et al., 1997; Fernández-
Real et al., 2003). Where acute inflammatory responses are seen as a normal response to help 
protect the body and allow for its repair, chronic inflammation remains long after the initial 
challenge. IL-1, IL-2, IL-3, IL-10, IL-12, transforming growth factor (TGF)β and TNF are amongst 
the cytokines that are implicated in chronic inflammation (Feghali et al., 1997). Although 
inflammation is necessary for protection against pathogens, if this is allowed to continue for a long 
period of time, chronic inflammation can lead to organ failure, shock and ultimately, death (Pruitt 
et al., 1995). 
Sterile inflammation is unique in that it occurs without the presence of microorganisms. 
Sterile inflammation is driven by the production of endogenous damage-associated molecular 
patterns (DAMPs) released due to injury and is typically due to ischemia reperfusion injury (IRI), 
chemical exposure or physical trauma (Chen et al., 2010). IRI occurs when blood flow to tissue is 
stopped and subsequently restored. The hypoxia and reoxygenation causes inflammation, which 
can lead to acute kidney damage and myocardial infarction (Shen et al., 2013). The inflammatory 
response that follows this injury is similar to that of a microbial challenge. 
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  DAMPs are non-microbial stimuli derived from the host and can be released in the event 
of cell death, leading to an inflammatory response (Chen et al., 2010). Bone morphogenetic protein 
(BMP)-1, granzyme B, matrix metalloproteinase (MMP)-2, MMP-13 and MMP-3 are amongst the 
proteolytic enzymes that can release DAMPs that serve as ligands for TLRs leading to signalling 
(Schaefer, 2014). Intracellular DAMPs are derived from cell death via necrosis, leading to the 
release of endogenous molecules from various compartments of the cell including the cell 
membrane, cytosol, nucleus, mitochondria, the endoplasmic reticulum (ER) and the 
autophagosome. DAMPs released include uric acid, heat shock proteins, mitochondrial DNA, 
HMGB1, histones and IL-1α (Schaefer, 2014).  
 The leukocyte adhesion cascade is important to allow for leukocyte migration to the site of 
inflammation and effector functions to eventually lead to resolution of inflammation. This occurs 
when cell migrate through the endothelium and the leukocyte adhesion cascade can be broken 
down into three main steps: rolling of the cells that occurs through selectin interaction, activation 
of leukocytes mediated by chemokines and arrest of cell movement through integrin binding (Ley 
et al., 2007). This allows for cells including neutrophils and monocytes to transmigrate through 
vessel walls and accumulate at the site of infection or injury (Ley et al., 2007). 
1.4.1. Pro-inflammatory and anti-inflammatory cytokines 
Cytokines can be broadly classed into pro-inflammatory and anti-inflammatory categories. 
Pro-inflammatory cytokines, as its name suggests, are involved in initiating and perpetuating an 
inflammatory response and anti-inflammatory cytokines can downregulate this. The outcome of 
cytokine signalling is dependent on the balance between pro-inflammatory and anti-inflammatory 
cytokines in the local environment. Typical functions of cytokine categories are outlined in Table 
2. Broadly, IL-1 and TNF can be pro-inflammatory, IL-3 is involved in haematopoietic stem cell 
proliferation and differentiation (Ihle, 1992), and granulocyte-macrophage colony stimulating 
factor (GM-CSF) acts to promote the secretion of inflammatory cytokines (Zhang et al., 2007). 
IFNγ, IL-12, IL-18 and IL-6 can also be pro-inflammatory whereas cytokines such as IL-10, IL-
13, IL-4, TGFβ and IFNα are stipulated to be anti-inflammatory as they can prevent the release of  
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pro-inflammatory cytokines (Cavaillon, 2001).  
Table 2: Major classes of cytokines and their general function.  
Classes include interferons, interleukins, colony-stimulating factors and tumour necrosis factors. Adapted 
from (Tisoncik et al., 2012). 
Cytokines can be pleiotropic in its ability to activate multiple cell types and this activation 
occurs through a receptor-ligand interaction. Aberrant or excessive secretion of cytokines can lead 
to local tissue damage and organ destruction, which is why it is important that the expression of 
these cytokines is tightly regulated.  
Type of cytokine Action of cytokine 
Interferons Regulate the innate immune system 
Anti-proliferative effect 
Activate anti-viral responses 
Interleukins Regulate cell growth, survival, differentiation and motility 
Stimulate immune responses and inflammation 
Colony-stimulating factors Promote proliferation and differentiation of haematopoietic 
progenitor cells 
Tumour necrosis factors Activate cytotoxic T lymphocytes 
Proinflammatory  
 1.4.2. The significance of inflammation in disease 
Inflammation is involved in various different conditions from neurodegenerative disorders, 
RA and IBD to sore throats. Atherosclerosis is suggested to occur when there is endothelial 
dysfunction caused by trauma from various sources including hypertension, free radicals from 
smoking, increased levels of low density lipoprotein (LDL) and other factors (Ross, 1999). This 
disruption leads to a continuous inflammatory response, remodelling of the arterial wall and 
increased recruitment of monocytes and T cells from the blood, which release chemokines and 
growth factors to cause necrosis (Ross, 1999). In addition, chronic inflammation is a causal factor 
in many types of cancers, with one example being IBD leading to colon carcinomas (Shacter et 
al., 2002). It has been speculated that immune cells recruited to the site of infection generate 
soluble factors and metabolites that increase angiogenesis and oncogene activation, leading to an 
uncontrolled proliferation of cells (Shacter et al., 2002).  
Sterile inflammation has been linked to gout, a type of arthritis where there is deposition 
of monosodium urate crystals (MSU) in the joint of patients thus inducing infiltration of immune 
cells, the destruction of healthy cartilage and chronic inflammation (Chen et al., 2010; Martillo et 
al., 2014). In addition, Alzheimer’s disease (AD), a degenerative brain disease, is driven by 
amyloid-β deposition that can activate microglial cells (resident macrophages of the central 
nervous system) and induce the complement cascade (Weiner et al., 2006). Interestingly, the use 
of anti-inflammatory drugs (NSAIDs) has shown promise by reducing the prevalence of AD 
(McGeer et al., 1996). Age-associated diseases can also be considered a form of chronic 
inflammation, termed ‘inflammaging’. This is a steady-state systemic aggravation in which 
damaged cells or molecules that are not eliminated can accumulate and act as DAMPs, thus 
activating innate immunity (Franceschi et al., 2014).  
1.5. A brief history of the IL-1 family 
In 1955, Atkins and Wood observed a transferable endogenous pyrogenic protein that could 
cause fever in rabbits (Atkins et al., 1955) and this was eventually known as leukocytic pyrogen 
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(LP). In work following that, LP was identified to be the same protein as lymphocyte activating 
factor (LAF), which is produced by macrophages to activate proliferation of T cells (Rosenwasser 
et al., 1979). In 1979, LP/LAF was designated ‘Interleukin-1’ in a letter to the editor of the Journal 
of Immunology (Mizel et al., 1979). Today, the IL-1 super family consists of 11 ligands (Table 3) 
and 10 receptors (Table 4) that can convey both pro- and anti-inflammatory effects and modulate  
immunity. IL-1α, IL-1β and IL-33 are the most studied members and the IL-1 family members 
play key roles in promoting and controlling inflammation.
IL-1 Ligands Function 
IL-1α / IL-1F1 Ligand 
IL-1β / IL-1F2 Ligand 
IL-33 / IL-1F11 Ligand 
IL-18 / IL-1F4 Ligand 
FIL-1ε / IL-1F6 Ligand 
IL-1ε / IL-1F9  Ligand 
IL-1H2 / IL-1F8 Ligand 
FIL-1δ / IL-1F5 Anti-inflammatory 
IL-1ζ / IL-1F7 Anti-inflammatory 
IL-1RA / IL-1F3 Receptor antagonist 
IL-1Hy2 / IL-1F10 Receptor antagonist 
Table 3: Members and function of the IL-1 cytokine family (Adapted from Dinarello 2009). 
IL-1 Receptors Function 
IL-1R1 Activating receptor for IL-1 
IL-1R2 Decoy receptor for IL-1 
IL-1RAcP Co-receptor for IL-1R1 
ST2 Inhibitor of signalling of IL-1, receptor for IL-33 
IL-18Rα Receptor for IL-18 
IL-18Rβ Signalling component for IL-18Rα 
IL-36R Receptor for IL-36 
SIGIRR Inhibits IL-1R1 and TLR4 signalling 
IL-1R9 Orphan receptor 
IL-1R10 Orphan receptor 
Table 4: Members and function of the IL-1 receptor family. 
 1.5.1. An introduction to key members of the IL-1 family  
 IL-1α, an important member of the IL-1 family, is expressed constitutively in healthy 
tissue by many different cell types including fibroblasts, epithelial and endothelial cells. IL-1α can 
be expressed intracellularly, on the cell membrane and also secreted/released into the extracellular 
space and it can be found in its full 33kDa precursor form (pro-IL-1α) that can be cleaved to a 
17kDa mature IL-1α. It is not known how IL-1α is released from cells to the extracellular 
environment as it lacks a signalling peptide to direct it to the ER-Golgi apparatus to be secreted. 
However, activators of the inflammasome can lead to IL-1α and IL-1β co-secretion and this is 
dependent or independent of the NLRP3 inflammasome based on the type of activator (Groß et 
al., 2012). Due to the expression of IL-1α in many different cell types, necrotic cell death can cause 
leakage of IL-1α, leading to an inflammatory response. Here, IL-1α acts as a DAMP or alarmin 
(an endogenous molecule that triggers an immune response), where it alerts the host to the insult 
that caused the initial cell death.  
 Another well-studied member of the IL-1 family, IL-1β, is found in a variety of cell types 
including macrophages and monocytes and is secreted, causing a large inflammatory response. IL-
1β can be found in its inactive 31kDa, precursor form (pro-IL-1β) and this can be cleaved to its 
mature 18kDa form, which has biological activity. IL-1β lacks a signal sequence and thus is also 
secreted via an unconventional pathway (Rubartelli et al., 1990). IL-1β secretion is a two-step 
process. When the cell encounters its first signal, a PAMP, the precursor form of IL-1β is produced. 
It then requires a second DAMP/PAMP signal in order to trigger IL-1β release (Lopez-Castejon et 
al., 2011). Some suggested methods of IL-1β release include IL-1β-containing micro vesicles 
being shed from the cell surface (MacKenzie et al., 2001) or release through pores made by 
gasdermin D (Heilig et al., 2018). Excessive production of IL-1β has been linked to diseases like 
RA, IBD, multiple sclerosis and AD (Ren et al., 2009).  
IL-33 is mainly expressed by endothelial and epithelial cells and like IL-1α, IL-33 also 
functions as an alarmin when released from cells as a result of necrosis (Miller, 2011). IL-33 binds 
to its receptor, ST2/IL-1RL1, which forms a complex with IL-1R accessory protein (IL-1RAcP) 
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and leads to the induction of TH2-like responses where IL-5 and IL-13 production is upregulated 
and increased eosinophil numbers are observed (Schmitz et al., 2005). IL-33 can be found in its 
precursor form and can be cleaved by caspase-1 but it has been reported that cleavage is not 
necessary for IL-33 activity (Talabot-Ayer et al., 2009). ST2 has been found on various cell types 
like cardiomyocytes, M2 polarised macrophages, mast cells, eosinophils, T cells and T regulatory 
cells (Griesenauer et al., 2017).  
1.5.2. IL-1 signalling and function 
The IL-1 receptor (IL-1R) family members typically have three immunoglobulin (Ig)-like 
chains in their extracellular domain and their intracellular domains contain a TIR domain 
(Garlanda, Dinarello, et al., 2013). TIR domains are intracellular signalling motifs found in IL-1R 
and TLRs that signal through the myeloid differentiation primary response 88 (MyD88) adaptor 
protein. The shape and structure of IL-1 ligands are similar to each other and the proteins have a 
conserved β-trefoil structure and fold into a symmetrical 12-anti-parallel-stranded β-barrel pattern 
(Krumm et al., 2014; Veerapandian, 1992) (Figure 1). IL-1R1 and IL-1 interact at two binding 
locations, with site mutagenesis studies showing four specific residues that are crucial for receptor 
binding and activation (Krumm et al., 2014). IL-1RAcP is a co-receptor for IL-1R1 and cells that 
are deficient in IL-1RAcP have been found to not respond to IL-1 stimulation (H. Wesche et al., 
1996). IL-1RAcP is vital for the signal transduction of IL-1R1, allowing for the coupling of 
downstream signalling molecules such as the IL-1 receptor-associated kinase (IRAK) and other 
kinases (Holger Wesche et al., 1997). 
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 IL-1α and IL-1β are translated as their precursor form and these can be cleaved by 
proteases into mature, shorter forms. Both IL-1α and IL-1β bind to the signalling receptor, IL-1R1 
and IL-1 activity can be sequestered by binding to IL-1R2 (Figure 2). Despite being able to bind 
to the same receptors, IL-1α and IL-1β only have 26% sequence homology (March et al., 1985). 
Binding of IL-1 to IL-1R1 causes the recruitment of IL-1RAcP followed by recruitment of MyD88 
via the TIR domains (C. Dinarello, 2011). This receptor complex then recruits IRAK-1, IRAK-2 
and the TNF Receptor-Associated Factor 6 (TRAF-6), leading to Nuclear Factor kappa-light-
chain-enhancer of activated B cells (NFκB) activation. The NFκB pathway is induced in 
inflammation and causes transcription of pro-inflammatory cytokines, chemokines and allows for 
cell survival (Lawrence, 2009).  
Figure 1: IL-1 cytokine superfamily individual and composite structures.  
Superimposing the individual human cytokines shows a hydrophobic core that is conserved. Taken from 
Krumm et al. (2014). 
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IL-1α is conventionally known to be cleaved by calpain, Granzyme B, chymase and 
neutrophil elastase. More recently, it has been reported that thrombin (Burzynski et al., 2019) and 
caspase-5/11 (Wiggins et al., 2019) can also cleave/activate IL-1α. Both forms of IL-1α have 
biological activity with the mature form displaying more bioactivity (Afonina et al., 2011; Zheng 
et al., 2013). IL-1β is biologically inactive in its precursor form and is cleaved by active caspase-
1, which is part of the inflammasome. The inflammasome is a complex that consists of a PRR that 
recognizes PAMPs, adaptor molecules and pro-caspase-1 (Lopez-Castejon et al., 2011). An 
example of an inflammasome is the well-characterised NLRP3 complex, which has an N-terminal 
pyrin domain (PYD). This can recruit the apoptosis-associated speck-like protein (ASC), an 
adaptor protein containing a caspase recruitment site that enables the inactive pro-caspase-1 to be 
recruited, leading to its activation and subsequent IL-1β processing and secretion (Lopez-Castejon 
Figure 2: The IL-1 signalling pathway in cells.  
The factors that can inhibit and promote IL-1 signalling are indicated. IL-1 binding to IL-1R1 leads to IL-
1R1 and IL-1RAcP forming a complex with MyD88. This allows for the recruitment of IRAK-1, IRAK-2 and 
TRAF-6, which leads to NFκB activation and translocation to the nucleus and expression of cytokines and 
factors that promote inflammation.  
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et al., 2011). It has also been reported that caspase-1 has a role in regulating IL-1α secretion, where 
the authors showed a decrease in IL-1α secretion in Casp1-/- macrophages (Keller et al., 2008). 
Gasdermin D, a pore-forming protein leading to pyroptosis, has also been shown to be vital for IL-
1β secretion (Kayagaki et al., 2015). Besides that, proteinase 3 can also process IL-1β (Coeshott 
et al., 1999).  
As a result of IL-1 release and signalling, neutrophils are activated to release oxygen and 
nitrogen radicals whereas macrophages and other phagocytes are induced to phagocytose invading 
pathogens. IL-1 signalling also upregulates the secretion of pro-inflammatory cytokines like IL-6 
and TNF and adhesion of monocytes and neutrophils to endothelial cells is also promoted (Figure 
3). Besides this, IL-1 signalling can lead to release of chemokines such as IL-8, a powerful 
chemoattractant for neutrophils, from macrophages and this begins an inflammatory cascade to 
recruit other immune cells (Turner et al., 2014).  
Figure 3: IL-1α cleavage leads to the subsequent recruitment and activation of various immune cells. 
Pro-IL-1α is released by necrotic cells and it can be cleaved and activated by enzymes like calpain, 
granzyme B, chymase and neutrophil elastase. The mature form of IL-1α goes on to act on other immune 
cells and this can lead to effects as indicated. (Adapted from Afonina et al. 2015) 
 26 
 Il1r1-/- mice are shown to have defective acute phase responses and high susceptibility to 
infection by Listeria monocytogenes (Labow et al., 1997), demonstrating the importance of IL-1 
signalling. IL-1R1 has been reported to be expressed by TH17 cells (Cosmi et al., 2008; Guo et al., 
2009; Maggi et al., 2012), T cells (Ghiringhelli et al., 2009; Klarnet et al., 1989), B cells 
(Matsushima, Akahoshi, et al., 1986), monocytes (C. Dinarello, 1991; Rosenwasser et al., 1979; 
Vasilyev et al., 2015), fibroblasts (Kawaguchi et al., 1992; Shimizu et al., 2015), iNK cells 
(Hughes et al., 2010) and neurons (Farrar et al., 1987). IL-1R1 has also been stipulated to be 
ubiquitous on all innate immune cell types including neutrophils, macrophages, eosinophils, 
basophils and mast cells (Garlanda, Dinarello, et al., 2013; Groß et al., 2012; Song et al., 2018). 
However, pilot studies in our lab along with data in the literature suggest that some immune cells 
including macrophages (Brint et al., 2004) and neutrophils (Shimizu et al., 2015) do not secrete 
pro-inflammatory cytokines in response to IL-1 stimulation. 
1.5.3. IL-1 signalling inhibition 
As IL-1 signalling is potent and has a wide range of effects on many different cells, it is 
important that it is kept in check to prevent any aberrant activity that can cause chronic 
inflammation. Due to IL-1 being active in its precursor form and expressed constitutively in cells, 
there is a need for strict regulation of signalling. Soluble IL-1 is not normally present in the 
circulation and elevated levels are found only in disease states such as AD (Italiani et al., 2018), 
hypertension (Dalekos et al., 1997), fulminant hepatic failure (Sekiyama et al., 1994) and sepsis 
(Cannon et al., 1990).  
IL-1R2 is a decoy receptor that has a similar structure to IL-1R1 (around 28% sequence 
homology) (Garlanda, Riva, et al., 2013) and IL-1R2 can bind to IL-1 with high affinity but the 
truncated intracellular tail lacks a TIR domain, and thus binding does not lead to downstream 
signalling. IL-1R2 can exist as a soluble, intracellular or membrane-bound protein, with IL-4 
stimulating its upregulation (Colotta et al., 1993). Soluble IL-1R2 can be produced by enzymes 
like metalloproteinases that cause IL-1R2 to be shed from the plasma membrane (Lorenzen et al., 
2012; Orlando et al., 1997). IL-1R2 can also bind to pro-IL-1β and prevent its processing to the 
mature form (Symons et al., 1995). Besides sequestering IL-1, IL-1R2 also forms a complex with 
IL-1RAcP upon IL-1 binding, preventing IL-1RAcP from forming a complex with the signalling 
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receptor IL-1R1 (Lang et al., 1998). In addition, IL-1R2 has been found to bind to the precursor 
form of IL-1α intracellularly and prevent its cleavage (Zheng et al., 2013). IL-1R2 has been found 
in B cells, neutrophils, monocytes and macrophages (Colotta et al., 1996; Garlanda, Riva, et al., 
2013).  
IL-1 receptor antagonist (IL-1RA) binds to IL-1R1 to prevent IL-1 from binding and 
signalling, also resulting in the sequestration of IL-1R1. IL-1RA can be secreted by macrophages, 
monocytes and neutrophils and also be found in the intracellular compartments of monocytes and 
fibroblasts (Andersson et al., 1992; Arend et al., 1998; Muzio et al., 1995). Although IL-1 and IL-
1RA have similar structures, IL-1α and IL-1β interact with IL-1R1 at two sites whereas IL-1RA 
only interacts with IL-1R1 at one site and binding at the second site is required for biological 
activity (Evans et al., 1995). Additionally, it has been reported that IFNs can inhibit both IL-1α 
and IL-1β transcription and translation (Mayer-Barber et al., 2011, 2014; Novikov et al., 2011). 
Type 1 IFNs have also been shown to activate the production of IL-1RA and IL-10, which is 
postulated to inhibit the effect of IL-1 (Aman et al., 1994; Fiorentino et al., 1991; Guarda et al., 
2011).  
1.5.4. The significance of IL-1 in disease 
The importance of IL-1 can be seen in the extent of its involvement in the pathogenesis of 
various diseases. IL-1 is involved in diseases like IBD, RA, cancer, atherosclerosis and diabetes, 
highlighting the value of studying the mechanisms by which IL-1 ligands act and the factors that 
can promote or prevent IL-1 signalling. In Type 2 diabetes, secretion of IL-1β by the pancreatic 
islet cells can lead to insulin-producing-beta cell destruction and the inhibition of IL-1β is reported 
to improve the condition (Maedler et al., 2009). IL-1 has also been implicated in angiogenesis, 
cancer and macular degeneration and blocking IL-1 with IL-1RA leads to better prognosis in those 
diseases (C. Dinarello, 2011; Hickish et al., 2017; Voronov et al., 2003). 
The balance between IL-1RA and IL-1 in tissues is important because it has been suggested 
that the underproduction of IL-1RA along with the overproduction of IL-1 can contribute to the 
pathogenesis of inflammatory diseases such as arterial diseases, graft-versus-host disease and 
central nervous system diseases (Arend, 2002). IL-1RA produced by macrophages and neutrophils 
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has been found to be upregulated in the synovial fluid of patients with RA (Arend, 2002; Malyak 
et al., 1993) however, this is reported to be in insufficient quantities to counteract the inflammatory 
effects of IL-1α and IL-1β also produced (Firestein et al., 1994). IL-1 found in the synovial fluid 
of RA patients has been suggested to lead to increased recruitment of immune cells, proteoglycan 
degradation and collagen degradation, thus perpetuating an inflammatory environment in the joints 
(Arend, 2002). 
IL-1 secretion is also increased in infectious lung diseases and IL-1, along with TNFα led 
to increased lung tissue damage, mitigated by treatment with IL-1RA (Mulligan et al., 1992). In 
atherosclerosis, mice deficient in IL-1RA have uncontrolled vascular inflammation (Merhi-Soussi 
et al., 2005). In addition, knock-downs (KD) of IL-1R1 is also seen to lead to decreased oncogene-
induced senescence, implicating IL-1 signalling in the senescence (Acosta et al., 2013). The 
CANTOS trial showed that canakinumab, an therapeutic monoclonal antibody that targets IL-1β 
leads to significant decrease in cardiovascular events compared to the placebo treatment, indicating 
the potent effects of IL-1 in disease (Ridker et al., 2017)r. 
1.6. In the spotlight: intracellular and secreted IL-1α  
IL-1α expression can be induced when cells are exposed to stimulation by hormones, 
oxidative stress, fatty acids, cytokines and TLR ligands (Di Paolo et al., 2016). The transcription 
factor activator protein 1 (AP-1) and the NFκB protein complex are required for IL-1α 
transcription (Bailly et al., 1996) and it has been reported that IL-1α expression is controlled by 
the methylation of CpG nucleotides in the proximal promoter region (van Rietschoten et al., 2006). 
IL-1α can be expressed on the cell membrane or secreted by stressed or damaged cells to induce 
more IL-1 secretion by neighbouring cells thus sustaining a pro-inflammatory loop (Di Paolo et 
al., 2016).  
The intracellular IL-1α (icIL-1α) precursor is expressed constitutively in healthy cells of 
mesenchymal origin such as epithelial cells and fibroblasts, and in immune cells such as 
macrophages and monocytes, where expression has to be induced (Cohen et al., 2010; Di Paolo et 
al., 2016). IL-1α can be bound to chromatin and when cells are perturbed, stressed and become 
necrotic, IL-1α can be released from the chromatin to induce pro-inflammatory responses. 
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However, in apoptotic cells, precursor IL-1α bound to chromatin in the nucleus is contained and 
not released into the extracellular space thus not eliciting a response (Cohen et al., 2010). Despite 
that, if apoptotic bodies containing IL-1α are not rapidly cleared, sterile inflammation can be 
induced (Berda-Haddad et al., 2011).  
Caspase-1, previously known as IL-1β-converting-enzyme (ICE) is a protease that 
processes IL-1β, IL-18 and IL-33 (Ogura et al., 2006; Thornberry et al., 1992) and caspase-1 
deficient mice are resistant to endotoxic shock and unable to activate the aforementioned cytokines 
(P. Li et al., 1995). Surprisingly, Casp1-/- macrophages were also found to produce decreased 
amounts of secreted IL-1α (Keller et al., 2008; P. Li et al., 1995). It has also been shown that 
activation of caspase-1 by inflammasome complexes is linked to the secretion of the IL-1α 
precursor although the specific mechanisms by which caspase-1 is involved in IL-1α production 
is still unknown (Keller et al., 2008).  
The positions of IL-1α cleavage by various proteases are marked in Figure 4 (Afonina et 
al., 2011; Kobayashi et al., 1990). This cleavage leads to the production of an N-terminal pro-piece 
consisting of the nuclear localisation signal (NLS) and a C-terminal mature active IL-1α. It is 
unknown whether there are differences between the mature IL-1α generated from cleavage by the 
various proteolytic enzymes at different residues. Calpain cleavage of IL-1α requires calcium and 
precursor IL-1α has about 50 times less affinity for IL-1R1 when compared to cleaved IL-1α 
(Zheng et al., 2013). Calpain is found ubiquitously and defects in its expression can be lethal 
(Sorimachi et al., 2012). Granzyme B is found in CD8+ T cells and NK cells and it processes IL-
1α within the cell and extracellularly (Afonina et al., 2011). In addition, it has also been discovered 
that precursor IL-1α can be cleaved by thrombin, indicating a link between the coagulation system 
and the IL-1α inflammatory response. Thrombin cleavage of IL-1α results in a p18 IL-1α that has 
been shown to be upregulated in patients with sepsis-associated acute respiratory distress 
syndrome (ARDS) (Burzynski et al., 2019).  
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IL-1α has been implicated in many diseases including AD where upregulation of IL-1α is 
linked to susceptibility to disease as amyloid precursor protein production is dependent on IL-1α 
(Du et al., 2000). Cancer cachexia is a wasting disease that impairs the ability of the host to fight 
infection and endure chemotherapy, and the hallmarks of this include anorexia, weight loss and 
anaemia (Dhanapal et al., 2011). To ease cancer cachexia, an anti-IL-1α monoclonal antibody, 
MABp1, has been tested in patients to neutralise IL-1α expressed on the cell surface of monocytes 
and platelets with relative success (Hong et al., 2014). In atherosclerosis, IL-1α derived from 
macrophages has been reported to perpetuate atherogenesis and fatty acids accumulated in 
atherosclerotic plaques selectively induce IL-1α expression by foam cells (Freigang et al., 2013).  
1.6.1. Cell surface IL-1α  
Cell surface IL-1α (csIL-1α) was first reported in 1985 where it was found to increase 
proliferation of T cells and enhance thymocyte activity (Kurt-Jones et al., 1985). Primary mouse 
peritoneal macrophages were stimulated with heat-killed Listeria monocytogenes, fixed in 
formaldehyde and incubated with T cells, leading to increased T cell numbers. Kurt-Jones and 
colleagues stipulated that the fixed macrophages were metabolically inactive and that this csIL-1α 
effect was independent from IL-1 secretion. They showed that T cell proliferation was abrogated 
with an anti-IL-1 antibody and this activity was presumed to be due to csIL-1α. It was later shown 
that csIL-1α is in its precursor form (Beuscher et al., 1988).  
Since its discovery, besides being found on macrophages (Brody et al., 1989; C. Dinarello, 
1991), csIL-1α has been detected on bone marrow-derived DCs (BMDCs) (C. Dinarello, 1991; 
Fettelschoss et al., 2011), human monocytes (Conlon et al., 1987; Garlanda, Dinarello, et al., 2013; 
Figure 4: Cleavage of precursor IL-1α by neutrophil elastase (NE), granzyme B (GzmB), chymase and 
calpain at specific residues.  
This generates a pro-piece IL-1α containing the NLS and a biologically active mature IL-1α. Taken from 
Afonina et al. (2015). 
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Inamura et al., 1989), human peripheral blood mononuclear cells (PBMCs) (Kaplanski et al., 
1994), B cells (Santarlasci et al., 2013a), endothelial cells (C. Dinarello, 1991) and fibroblasts (C. 
Dinarello, 1991; Orjalo et al., 2009). IL-1α does not contain a signal sequence to direct it to the 
ER to be synthesised, nor does it contain hydrophobic regions for interaction with the cellular 
membrane and thus, it is poorly understood how csIL-1α is tethered to the surface of cells. 
It has been reported that csIL-1α is associated with the membrane through a lectin-like 
interaction and this can be displaced by D-mannose treatment (Brody et al., 1989). The authors 
showed that D-mannose, but not D-fucose treatment of fixed macrophages led to increased IL-1 
biological activity in the supernatants and that the 33kDa pro-IL-1α can be immunoprecipitated 
from those supernatants. In addition, myristoylation of two highly conserved residues, Lys-82 and 
Lys-83 in the pro-IL-1α sequence has been suggested to allow for csIL-1α targeting to the plasma 
membrane (Stevenson et al., 1993). 
1.6.1.1. The controversy: is csIL-1α an artefact? 
csIL-1α was discovered on the plasma membranes of fixed murine macrophages (Kurt-
Jones et al., 1985). At the time, fixation of macrophages was stipulated to crosslink the cell surface 
epitopes in place to allow for csIL-1α detection whilst preventing icIL-1α from leaking out of the 
cell. csIL-1α detection was carried out by the indirect thymocyte proliferation bioassay. Despite 
reports of csIL-1α on various cell types, the existence of csIL-1α has been refuted due to evidence 
of false positive detection of leaked icIL-1α in the supernatants after the fixation process, thus 
increasing thymocyte proliferation (Minnich-Carruth et al., 1989). It has also been revealed that 
both IL-1α and IL-1β are secreted after fixation up to 96 hours (Bailly et al., 1990). Minnich-
Carruth et al. (1989) provided evidence that there was significant IL-1α leakage from cells fixed 
with formaldehyde, even after 24 hours of fixation, washing and an additional 72 hours of 
incubation (Minnich-Carruth et al., 1989). This suggests that further examination is required to 
determine the existence of csIL-1α and to distinguish its effects from secreted IL-1α.  
1.6.1.2. csIL-1α in senescence 
Senescence is the process by which genomic instability and telomere shortening causes the 
inhibition of proliferation of damaged or aged cells (McHugh et al., 2018). This occurs as part of 
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the aging process and the phenotypic changes include increased autophagy, metabolic 
reprogramming and chromatin remodelling (Kuilman et al., 2010). The senescence-associated 
secretory phenotype (SASP) is expressed by senescent cells, where there is an increased secretion 
of pro-inflammatory cytokines, chemokines and growth factors (Coppé et al., 2010). The SASP 
leads to recruitment of immune cells like CD4+ T cells, NK cells and macrophages to clear 
senescent cells, thus acting as a tumour suppressive mechanism by preventing the proliferation of 
cells that have genomic instability or mutations (McHugh et al., 2018; Xue et al., 2007). However, 
on the other side of the coin, the SASP has also been implicated in promoting proliferation of 
epithelial cells, thereby enhancing tumorigenesis in breast cancer (Krtolica et al., 2001) and 
prostate cancer (Bavik et al., 2006).  
csIL-1α has been reported to be indispensable in regulating IL-6/IL-8 secretion as part of 
the SASP. The incubation of a monoclonal antibody against IL-1α with senescent cells led to 
decreased IL-6 and IL-8 secretion, also implicating IL-1R1 signalling in the process (Orjalo et al., 
2009). Caspase-5 has also been implicated in the csIL-1α-dependent SASP regulation where 
caspase-5 knock-down in human cells showed decreased csIL-1α and reduction in IL-6, IL-8 and 
MCP-1 (Wiggins et al., 2019). In addition, the mammalian target of rapamycin (MTOR), is 
involved in regulating cell metabolism and growth and rapamycin is the drug that inhibits this 
pathway (J. Li et al., 2014). Rapamycin has been reported to supresses the SASP by inhibiting 
csIL-1α translation, leading to subsequent decreased IL-6 secretion (Laberge et al., 2015).  
1.7. Aims of the project 
The aims of this PhD project are two-fold, 
1. To determine if macrophages respond to IL-1 stimulation and if not, to understand 
why. 
Macrophages are widely reported to express IL-1R1 and commonly thought to 
secrete pro-inflammatory cytokines like TNFα and IL-6 when treated with IL-1. However, 
pilot data from our lab suggests that macrophages do not respond to IL-1 stimulation. 
Given that macrophages respond to lipopolysaccharide (LPS) and this shares the same 
 33 
signalling adaptors as IL-1, we aim to understand the level at which IL-1 signalling is 
inhibited, potentially revealing novel mechanisms that regulate IL-1 signalling. 
2. To determine if csIL-1α is real or an artefact, identify factors that control its 
expression and investigate how csIL-1α is tethered to the plasma membrane. 
As the existence of csIL-1α has been disputed, we aim to determine if we can create 
a robust protocol to identify true csIL-1α. We will examine the connection between icIL-
1α, csIL-1α and secreted IL-1α. In addition, we will determine how csIL-1α is associated 
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2. Materials and Methods 
2.1.  Mice 
Adult C57Bl/6 male mice between 8-12 weeks of age were used in experiments. All 
procedures were carried out by the author in accordance with the Animals Scientific Procedures 
Act (1986) and has been licensed by the Home Office of the United Kingdom. IL-1α-/- mice were 
generated as stated in Horai et al. (1998). Briefly, embryonic stem cells were electroporated with 
an IL-1α targeting vector, which deleted a DNA fragment of 1.5kb between two sites in exon 5 
and intron 5 and this also resulted in the deletion of the N-terminal coding region for mature IL-
1α. The embryonic stem cells were grown and injected into mouse embryos then implanted into a 
female mouse uterus to allow for the generation of pups. Crossbreeding was carried out in order 
to generate homozygous knockout mice (Horai et al., 1998). 
2.2. Cell culture 
2.2.1. Maintenance of J2, EL4, HeLa and IMR90 cell lines 
J2 macrophages (Gandino and Varesio 1990) and EL4 cells were cultured in full Roswell 
Park Memorial Institute (RPMI) 1640 Medium (Gibco 31870-025) (supplemented with 10% foetal 
calf serum (FCS), 5mg/ml L-glutamine, 10U/ml penicillin, 10mg/ml streptomycin and 50µM β-
mercaptoethanol). HeLa cells were cultured in full Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma-Aldrich D5671) (supplemented with 10% FCS, 5mg/ml L-glutamine, 10U/ml penicillin 
and 10mg/ml streptomycin). IMR90 cells were cultured in phenol red-free full Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen 31053) (supplemented with 10% FCS, 10% L-
glutamine, 10U/ml penicillin, 10mg/ml streptomycin, 1% pyruvate (Invitrogen 11360-070)). 
Senescence was induced in IMR90s with 4-hydroxytamoxifen (100nM) (Sigma-Aldrich H7904) 
over a 7-day period. All cells were kept at 80% confluence and passaged with trypsin (Sigma-
Aldrich T4049). Accutase (Sigma-Aldrich A6964) was used to detach cells for csIL-1α 
experiments. 
 36 
2.2.2. Primary murine bone marrow-derived macrophages  
Femurs and tibias of male C57BL/6 adult mice were rinsed in 70% ethanol followed by 
sterile Phosphate Buffer Solution (PBS) (Sigma-Aldrich D8537). The ends of the bones were cut 
off and bone marrow was flushed out using a 27-gauge needle. The cells were briefly pipetted to 
disperse any clumps and pushed through a 21-gauge needle and a 40µm nylon cell strainer. The 
cells were then counted and 10ml plated using full RPMI media (2x105 cells/ml, supplemented 
with 15% L929 cell-conditioned media) then differentiated into macrophages over a 7-day period 
in sterile non-tissue culture (TC)-treated petri dishes (Greiner 664102), with media refreshed every 
other day. 
For experiments, bone marrow-derived macrophages (BMDMs) were plated in non-TC 48-
well plates (Fisher Scientific 351178) (100 000 cells/well, 200µl/well) and incubated overnight 
(ON) (37°C). Cells were washed in PBS before treatment with LPS (1µg/ml Sigma-Aldrich 
L2630) (ON 37°C unless stated otherwise). 
For thrombin experiments, cells were collected, treated with thrombin (Merck Millipore 
69671) (0.01U/µl or 0.0025U/µl 30 mins RT) in Hanks’ Balanced Salt Solution (HBSS) (Gibco 
24020-083) then washed with PBS for flow staining. For emetine experiments, cells were treated 
with emetine (Sigma-Aldrich E2375 1nM) and LPS (ON 37°C) before washing and staining. For 
calpain and granzyme B experiments, BMDMs were detached, and treated with Calpain-1 (Sigma-
Aldrich 208713) (0.3µg/µl 1h RT or 37°C) or Granzyme B (human: 4U/µl Enzo BML-8E2338-
5000, murine: 28µg/ml Peprotech 140-03) (1h RT) in HBSS then washed for flow staining. For 
displacement experiments, BMDMs adhered to wells were washed after LPS stimulation and 
treated with IL-1RA (Sobi 29280-1A) (5h 37°C) in dilutions indicated. For TAPI-1 treatment, 
BMDMs were incubated in wells with TAPI-1 (Peptide International INH-3855-PI) (50µg/ml 20 
mins 37°C) prior to LPS incubation. If treated with mannose, D-mannose (Sigma-Aldrich M6020) 
or D-Fucose (Sigma-Aldrich F8150) were used in concentrations indicated (1h 4°C or RT or 
37°C). If treated with dexamethasone (Sigma-Aldrich D4902), 1µM, 10µM or 100µM of 
dexamethasone was used to treat the cells with LPS was (1µg/ml ON 37°C). 
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2.2.3. Primary murine peritoneal macrophages  
Peritoneal macrophages were elicited to the peritoneum of mice with 1ml 3% sterile 
thioglycolate broth (Oxoid CM0391) injected into the peritoneal cavity of adult mice (Zhang, 
Goncalves, and Mosser 2008). The mice were culled after 4 days, the abdomen sterilised and an 
incision made along the midsection of the mouse. 10ml of cold PBS was injected through the 
peritoneal wall and recovered without puncturing any organs. Cells were centrifuged (400g 10 
minutes), resuspended in full DMEM then cultured (1x106 cells/well) in 6-well tissue culture plates 
and incubated (1.5h 37°C). Cells were washed three times with PBS to remove non-adherent cells. 
Adherent cells were detached and used for experiments. 
2.2.4. Primary murine fibroblasts  
Murine ear tissue was obtained and rinsed with 70% ethanol followed by sterile PBS. The 
tissue was minced and incubated in trypsin (2ml 1h 37°C) and regularly vortexed. Full DMEM 
was added and the mixture was spun (350g 5 mins RT) and cells resuspended in 1ml full DMEM. 
The suspension was transferred to 6-well TC-treated plates with the tissue weighed down by sterile 
22mm coverslips (Shandon 6776301) and the wells were topped up with full DMEM. Cells were 
incubated (3 days 37°C) and washed. Adherent cells were detached and used for experiments. 
2.2.5. Primary murine bone marrow dendritic cells 
Bone marrow cell suspensions were prepared an plated as outlined in Section 2.2.2. 
Recombinant murine (rm)-GM-CSF (Peprotech 315-03 20ng/ml) was added and cells were 
incubated (7 days 37°C), with media refreshed every other day. Loosely adherent cells and cells 
in suspension were collected for experiments. BMDCs obtained were 50-70% CD11c+ via flow 
cytometry.  
2.2.6. Primary murine neutrophils 
Blood drawn from cardiac puncture was obtained from mice and put into EDTA-coated 
tubes (Sarstedt 16.444) to prevent coagulation. Blood was pipetted up and down gently in the 
EDTA tubes to mix and red blood cell lysis buffer (Biolegend 420301) was added to blood and 
incubated (2ml 7 mins RT). Cells were washed and put through a 40µm cell strainer and split to 
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be treated (5x105 cells/sample). Cells were treated with LPS (1µg/ml Sigma-Aldrich) (2h 37°C), 
washed and stained. 
2.2.7. Primary murine splenocytes 
Spleens were harvested from adult mice and pushed through a 70µm nylon cell strainer 
and rinsed through with PBS. The cell suspension was passed through a 40µm nylon cell strainer 
and spun (350g 5 mins RT), incubated in red blood cell lysis buffer (eBioscience 00-4300 7 mins 
RT) and washed. Cells were resuspended in full RPMI then plated into 48-well TC plates and 
treated with LPS (1µg/ml Sigma) (ON 37°C). Cells in suspension were washed and stained to 
identify T and B cell populations. 
2.2.9. Primary human monocytes 
PBMC preparations and autologous serum were kindly provided by Professor Edwin 
Chilvers’ group from the Department of Medicine, University of Cambridge. Blood was collected 
and separated through Ficoll density gradient centrifugation. Samples were washed using full 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Gibco 21980-032) (supplemented with 10% L-
glutamine, 10U/ml penicillin, 10mg/ml streptomycin) and plated in sterile non-TC-treated petri 
dishes and incubated (1h 37°C). Cells that were not adhered were washed off with full IMDM and 
adherent monocytes were used for experiments. 
2.2.10. Primary human macrophages 
Primary human monocytes were prepared as stated in Section 2.2.9 and monocytes were 
cultured in full IMDM supplemented with 10% autologous serum for 6-7 days (with media 
refreshed every other day) until cells were differentiated into macrophages and were used for 
experiments. 
2.3. Flow cytometry 
Samples run through the flow cytometer consisted of ~5x105 cells/condition and were Fc 
blocked using Trustain FcX (Biolegend, murine: 101319; human: 422301) (1:100 10 mins RT) in 
flow buffer (1% BSA, 0.05% sodium azide in PBS) prior to staining. All conjugated antibodies 
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were stained for 30 mins RT with a Live/Dead (L/D) fixable far red stain (Thermofisher L10120 
1:1000). Samples were run on the Accuri C6 flow cytometer (BD Biosciences) to measure 
fluorescence. 
 
2.3.1. IL-1α staining 
Cells stained for csIL-1α were detached from plates by accutase (10 mins RT), collected 
then spun (300g 4 mins 4°C). The cells were Fc blocked, stained with an IL-1α primary antibody 
(Biolegend BL1a-89) (1:300 20 mins 4°C) and washed twice in flow buffer. Cells were stained 
with a secondary Streptavidin-Phycoerythrin (PE) (eBioscience 12-4317-87 1:1500) and L/D stain 
(20 mins 4°C) before a wash and run on the flow cytometer. Staining controls carried out include 
secondary only, unstained and fluorescence minus one (FMO) controls. If cell lineage markers 
were stained for, this was done at the secondary antibody and L/D stain step. If the experiment 
involved fixation, this was carried out before staining (15 mins RT) and samples were washed 
prior to staining. For icIL-1α staining, cells were fixed (2% formaldehyde 15 mins RT) and 
resuspended in intracellular permeabilization buffer (Biolegend 421002), Fc blocked and stained 
(antibody dilutions and washes carried out in permeabilization buffer). 
 
Species Target Antigen Fluorophore Dilution Company Clone 
Mouse IL-1α  PE 1:20  Biolegend ALF-161 
Mouse IL-1α  Unconjugated 1:300 Biolegend BL1a-89 
Mouse IL-1R1  PE 1:50 Biolegend JAMA-147 
Mouse Thy-1/CD90 PE 1:80 Biolegend 30-H12 
Mouse CD45 PECy7 1:100 Biolegend 30-F11 
Mouse CD115 PE 1:100 eBioscience AFS98 
Mouse CD11b AF488 1:800 Biolegend M1/70 
Mouse Ly6G PECy7 1:80 Biolegend 1A8 
Mouse B220 AF488 1:40 Biolegend RA3-6B2 
Mouse CD3 FITC 1:50 Biolegend 17A2 
Human IL-1α  FITC 1:10 R&D FAB200F 
Human IL-1R1 PE 1:100 R&D FAB269P 
Table 5: Mouse and human antibodies used in flow cytometry experiments.  
Fluorophores conjugated to the antibodies, dilutions used, manufacturing companies and clone numbers 
for each antibody are stated. 
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2.4. Bead enzyme linked immunosorbent assays (ELISA)  
For IL-1 response assays, cells were treated with rIL-1 (Peprotech 50ng/ml murine IL-1α 
211-11A; murine IL-1β 211-11B, human IL-1α 200-01A; human IL-1β 200-01B) or LPS-EK 
Ultrapure (Invitrogen LKP-39-01 20ng/ml) for time indicated at 37°C. For priming experiments, 
cells were primed with LPS (5h 37°C) then treated with IL-1 (ON 37°C). Supernatants were 
collected from these cells and frozen down (-20°C) or run immediately on bead-based ELISA kits 
to detect TNFα (murine: BD Biosciences 558299; human: Novex Life Technologies LHC3011M), 
IL-6 (murine: Novex Life Technologies LMC0061) or IL-1β (murine: Invitrogen EPX01A-26002-
901) secretion. These were carried out in 96-well 1.2µm filter plates (Merck Millipore 
MSBVN1250) in duplicates and were done following manufacturer’s instructions. In brief, the 
25µl samples were incubated with 25µl diluted capture beads provided in the kit in each well. The 
capture beads were diluted in assay diluent (1% BSA in PBS, filtered through a 0.45µm filter) and 
the samples were placed on a shaker for 5 minutes and incubated (1h RT). 25µl of diluted detection 
reagent from the kit was added into each well and shaken for 5 minutes. This was then incubated 
(1h RT) and the plate was applied to a vacuum manifold to drain the wells before adding 150µl to 
each well and run on the flow cytometer. The samples were then run on the flow cytometer to 
detect fluorescence and analysed compared to a standard curve. Mean values were derived from 
duplicates.  
2.4.1. IL-1α bioactivity assay 
To detect thrombin-cleaved csIL-1α bioactivity, BMDMs were plated into 96-well TC-
treated plates (7x104 cells/well 100µl/well ON 37°C) and treated with LPS (Sigma 1µg/ml ON 
37°C). Cells were then treated with thrombin (1:100 30 mins RT) and supernatants were collected 
and incubated with a thrombin inhibitor, PPACK (Enzo BML-PI117) (1:100 15 mins RT). These 
supernatants were then incubated with murine fibroblasts (1.2x104 cells/well 200µl/well in 48-well 
TC plates) at 25% concentration. Where appropriate, a neutralising IL-1 antibody (R&D AF400-
NA 8µg/ml) and/or recombinant IL-1α (Peprotech 100ng/ml) were added. Cells were incubated 
(5h 37°C) and supernatants were collected, spun (400g 4 mins 4°C) and frozen down (-20°C). The 
murine IL-6 bead ELISA was carried out with these samples based on the protocol specified in 
Section 2.4. 
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For Phosphatidylinositol Phospholipase C (PI-PLC)-treated samples, BMDMs were plated 
and treated with LPS as above then incubated with PI-PLC (Sigma-Aldrich P5542) (0.55U/ml or 
0.05U/ml in HBSS 3h 37°C). Supernatants were collected, spun and treated with thrombin (1:100 
30 mins RT) followed by PPACK (1:100 15 mins RT). These supernatants were then used to treat 
murine fibroblasts plated as specified above and the murine IL-6 bead ELISA carried out.   
2.5. Immunofluorescence  
Immunofluorescence (IF) was carried out on live BMDMs to visualize csIL-1α. BMDMs 
were grown on sterile 13mm coverslips (VWR 631-0149) in 24-well TC plates (2x105 
cells/coverslip 500µl/well ON 37°C). Coverslips were blocked in 1% BSA/PBS (1h RT) and 
incubated with the primary antibody (Biolegend BL1a-89 or Abcam ab7632) in dilutions and 
conditions indicated (1h or 30 mins RT or 4°C in humidified chamber) then washed four times 
(0.05%Tween/PBS) followed by incubation with the secondary antibody (1:400 Streptavidin 
AF488/goat anti-rabbit AF488) (1h or 30 mins RT or 4°C in humidified chamber) and four washes. 
BMDMs were then incubated with propidium iodide (PI) (1:1000 5 mins RT in the dark), washed 
four times, fixed (2% formaldehyde 15 mins RT), rinsed and mounted onto glass slides with 
ProLong Gold antifade mountant (Life technologies P36934). To visualise icIL-1α, BMDMs were 
grown on coverslips as specified above, followed by fixation (2% formaldehyde 15 mins RT), 
permeabilisation (0.5% NP40 Sigma-Aldrich 127087-87-0 1 min RT), blocking (1% BSA 1h RT), 
staining as specified above and mounting on glass slides. 
2.6. RNA purification and reverse transcription to cDNA 
RNA purification was carried out using the RNeasy mini kit (Qiagen 74104) in accordance 
to the manufacturer’s protocol. Briefly, less than 5 x 106 cells were disrupted in 350µl RLT buffer 
and 1 volume of 70% ethanol was added to the lysate and mixed well. The samples were transferred 
to a RNeasy spin column and centrifuged for 2 minutes. Flow through was discarded and 700µl of 
the RW1 buffer was added to the column and centrifuged with the flow through discarded. 500µl 
of the RPE buffer was added and centrifuged to discard flow through twice. 40µl of RNase-free 
water was placed on the column membrane and RNA was eluted. Eluted RNA concentration was 
quantified using the NanoDrop Spectrophotometer (Thermo Scientific ND-1000). 
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Samples were subjected to reverse transcription to obtain cDNA following the 
manufacturer’s protocol using the Reverse Transcription System (Promega, A3500). Briefly, 
1.5µg of RNA was incubated with the reagents below (10 mins 70°C): 
1. 1µl Oligo dT primer 
2. 0.5µl random primers 
3. 2µl dNTPs 
Samples were immediately placed on ice for a few minutes and a 20µl reaction was made with the 
RNA and the following reagents: 
4. 4µl MgCl2  
5. 2µl 10X Buffer 
6. 0.5µl RNAsin ribonuclease inhibitor 
7. 0.6µl high concentration AMV Reverse Transcriptase 
8. Nuclease-free H2O to 20µl  
The reaction was incubated at 25°C for 10 minutes then 50 minutes at 42°C followed by 5 minutes 
at 95°C and then 5 minutes at 4°C. 
2.7. Quantitative PCR 
1 µl of cDNA synthesized from the protocol in Section 2.6 was used in the quantitative 
PCR (qPCR) reaction using the AmpliTaq Gold DNA Polymerase kit (Life Technologies 
4486226). The other components of the reaction are as follows: 
1. 2µl of 10X Buffer  
2. 1.6µl of 25mM MgCl2 
3. 0.4µl 10mM dNTPs 
4. 0.1µl AmpliTaq Gold DNA Polymerase (5U/µl) 
5. 14.4µl H2O 
6. 1µl TaqMan probe (murine: Il1α Mm00439620, Il1r2 Mm00439629, St2/Il1rl1 
Mm00516117, Gusb Mm01197698, Tbp Mm01277042) 
The qPCR reactions were carried out in the Qiagen Rotorgene 6000 using the two-step 
programme which runs for 95°C for 10 minutes then 40 cycles of 95°C for 10 seconds followed 
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by 60°C for 45 seconds. Data obtained from this was analysed using the Rotorgene 6000 series 
software. 
2.8. Western blots 
Proteins were run on a SDS-PAGE gel (15% 0.75mm) with 15µl of samples in Laemmli 
buffer and 10µl of the standard (Biorad 161-0374). The gels were placed in a chamber filled with 
anode and cathode buffer and run (2h 100V) until the samples reached the bottom of the gel. The 
gels were placed in transfer buffer (250mM Tris base, 2M glycine pH 8.6) for equilibration (5 
mins shaking) and then blotted on a PVDF membrane (0.22µm pore size) (Biorad 162-0177) at 
0.085A/cassette (2h 4°C).The blots were disassembled and blocked in blocking buffer (5% Marvel 
milk powder in PBS, spun to remove sediment) (1h RT) and the gels were stained with Coomassie 
(Biorad 161-0787) (30 mins RT). The gels were then de-stained in H2O (5 mins shaking RT) then 
dried via vacuum suction.  
After blocking, the blots were incubated in the primary goat anti-mouse IL-1α antibody 
(R&D AF-400-NA 1:500 in 5ml blocking buffer) (ON 4°C shaking) then washed three times with 
wash buffer (0.05% Tween/PBS) and incubated with the secondary cow anti-goat HRP (Jackson 
805-035-186 1:2000 in 5ml blocking buffer) (1h RT shaking). The membranes were then washed 
three times with wash buffer and developed with ECL (GE healthcare RPN2106) and exposed 
onto film (Fujifilm).  
2.9. Cellular transfection for overexpressing IL-1R1 and IL-1RAcP 
The Amaxa mouse macrophage nucleofector kit (Lonza VPA-1009) was used to transfect 
BMDMs and J2 macrophages with 2µg of plasmid DNA. Cells were plated equally and incubated 
(ON 37°C) before transfection. Transfection was carried out using the manufacturer’s protocol and 
2µg of an empty control vector (pcDNA3), an IL-1R1 (pcDNA-3-IL-1R1) insert and/or an IL-
1RAcP vector (pcDNA3-IL-1RAcP) were used in the reaction. The plasmids were mixed with 
100µl of mouse macrophage nucleofector solution provided in the kit and electroporated using the 
Y-001 programme on the Nucleofector 2b machine. The transfected cells were then incubated (ON 
37°C) and then treated with LPS (20ng/ml) or rIL-1α (50ng/ml) (5h 37°C). The supernatant was 
collected and assayed for accumulated secretion of IL-6 and TNFα. To measure transfection 
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efficiency, a sample with 2µg of the pmaxGFP vector provided in the kit was transfected and used 
to visually confirm transfection and run on the flow cytometer (BD Biosciences) to compare GFP 
fluorescence levels with the control vector. 
2.10. RNAimax transfection 
The RNAimax transfections were carried out following manufacturer’s instruction. In 
brief, BMDMs were grown to 60-80% confluency. The Lipofectamine RNAiMAX Reagent 
(Thermofisher Scientific 13778030) was diluted in Opti-MEM medium (Thermofisher Scientific 
31985062 1:17). 12.5nM of siRNA (non-targeting siRNA D-001210-01-05; IL1A human siRNA 
D-007952-02-0002) was added delivered with RNAiMAX reagent and incubated (5 mins RT). 
This siRNA-lipid complex was added to the cells and incubated (24h 37°C).  
2.11. Processing of various tissues for csIL-1α staining 
A mouse was injected intraperitoneally with LPS (2mg/kg) and was culled after 6 hours. 
Peritoneal lavage was collected by exposing the inner skin of the peritoneal cavity lining followed 
by injection of 5ml cold PBS and collecting the cell suspension from the peritoneal cavity. Cells 
were extracted from the spleen as specified in Section 2.27. Lungs were harvested by exposing the 
thoracic cavity and were washed and minced finely. This was digested in collagenase (1mg/ml) 
and elastase (0.25mg/ml) (45 mins 37°C) and put through a 100µm cell strainer followed by a 
70µm cell strainer. The cell suspension was washed twice and cells were dispersed using a syringe 
fitted with a 23-gauge needle three times. Subcutaneous adipose tissue was harvested and minced 
into fine pieces. The homogenate was digested with collagenase (4mg/ml 20 mins 37°C shaking) 
and passed through a 100µm cell strainer. The cell suspension was centrifuged (500g 10 mins 4°C) 
and resuspended for staining. 
2.12. Statistical Analyses 
All statistical tests were carried out on the GraphPad Prism software. When comparing two 
groups of samples, the unpaired t-test was used to determine the p value. If comparing more than 
two groups of samples with a one independent variable, the one-way ANOVA test was used. To 
determine the interaction between two independent variables with more than two groups of 
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samples, the two-way ANOVA test was used. If the ANOVA tests return with a statistically 
significant result, post hoc tests were carried out. To compare every mean to every other mean, the 
Tukey’s test was carried out. To compare every mean to a control mean, the Dunnett’s tests was 
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Results: Macrophage response to IL-1 stimulation  
3. Macrophage secretion of pro-inflammatory cytokines in response to IL-1 is dependent 
on IL-1R1 
3.1. Introduction  
IL-1α and IL-1β signalling occurs through IL-1R1, which recruits the IL-1RAcP and 
eventually leads to NFκB activation and secretion of cytokines, including TNFα and IL-6. This 
signalling can be inhibited by IL-1R2, a decoy receptor that lacks an intracellular signalling 
domain and sequesters IL-1. IL-1R1 is reported to be on the surface of many different immune 
cells including macrophages and neutrophils (Garlanda, Dinarello, et al., 2013; Groß et al., 2012; 
Song et al., 2018). In addition, it has been reported that the M2b macrophage subset can be 
activated by IL-1R1 signalling (Fernando O. Martinez et al., 2014). Indeed, RNA-seq data of 
multiple blood cell types shows that human macrophages, DCs, monocytes and neutrophils from 
healthy individuals express IL-1R1 (Figure 5). 
Preliminary data from our lab show that macrophages do not secrete pro-inflammatory 
cytokines in response to IL-1 stimulation, similar to what was observed by Brint et al. (2004) and 
Shimizu et al. (2015), despite reports that the signalling receptor is expressed on these cell types. 
Figure 5: RNA-seq data showing IL-1R1 expression on various human immune cell types. (Data from Dr 
Mattia Frontini, Department of Haematology, University of Cambridge).  
p = venous blood,  = cord blood. 
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In keeping with this, pilot studies by the group indicated the presence of IL-1R1 on murine 
macrophages using a IL-1R1 antibody. It is a widely accepted view that most immune cells can 
respond to IL-1 as IL-1R1 is present on the cell surface. However, we do not understand why there 
is no secretion of pro-inflammatory cytokines when we treat murine macrophages with rIL-1. This 
is important to investigate because it may point to an additional regulatory mechanism for IL-1 
signalling. In addition, we would also like to see if these findings extend to BMDCs, human 
monocytes and macrophages or if this is simply relevant only to BMDMs. 
Shimizu et al. (2015) reported that the knock-out of Il1r2 in rIL-1-treated BMDMs and 
peritoneal macrophages led to recovery of IL-1 signalling, measured by pro-inflammatory 
cytokine secretion, despite low Il1r2 expression in murine macrophages. They also did not see any 
pro-inflammatory cytokine secretion in response to rIL-1 by WT macrophages and this suggests 
that there is a novel point of IL-1 signalling regulation that requires further investigation. We 
would also like to see if we can replicate the findings by Shimizu et al. (2015) and understand how 
IL-1R2 is inhibiting IL-1 signalling, perhaps through investigating different conditions that affect 
IL-1R2 expression and measuring the corresponding expression levels.  
ST2 is the receptor for IL-33 and can be in its soluble form or membrane-bound. It has 
been found to be expressed on mast cells (Moritz et al., 1998) and TH2 cells (Xu et al., 1998). 
Membrane-bound ST2 has been suggested to also be an inhibitor of IL-1R1 signalling by 
sequestering MyD88 and Mal adaptor proteins and knocking out this receptor leads to a recovery 
in IL-1 signalling, measured by IL-6, IL-12 and TNF release (Brint et al., 2004). Brint et al. (2004) 
also described ST2 to inhibit not only IL-1R1 signalling in macrophages, but also TLR4 signalling. 
LPS, which is the agonist to TLR4, is routinely used as a positive control because it elicits pro-
inflammatory cytokine secretion from macrophages. It would be interesting to see if St2-/- cells 
would lead to an overall increase in pro-inflammatory cytokine secretion compared to WT and 




3.2. BMDM differentiation protocol yields a high proportion of CD115+ macrophages  
We harvested bone marrow from C57BL/6 wild-type (WT) mice and differentiated them 
into macrophages following standard protocols (Trouplin et al., 2013). On Day 5 of differentiation, 
we stained these cells for CD115, which confirmed that 95% of adherent cells expressed CD115, 
indicating that they were likely to be macrophages (Figure 6). 
3.3. Murine macrophages do not respond to treatment with recombinant IL-1 
As IL-1 is involved in regulating pro-inflammatory responses and macrophages are 
reported to express IL-1R1, we examined IL-6 and TNFα release from J2 immortalised 
macrophages, primary murine BMDMs and peritoneal macrophages. J2 macrophages are made by 
transfecting BMDMs with a recombinant retrovirus carrying oncogenes and this immortalises the 
macrophages (Gandino et al., 1990). Treatment of macrophages with rIL-1 did not lead to 
increased IL-6 secretion (Figure 7A). TNFα secretion by J2 macrophages, primary BMDMs and 
peritoneal macrophages also did not increase in response to rIL-1 treatment (Figure 7B-E). 
Increasing the stimulation period from 5 hours to 24 hours did not lead to increased TNFα secretion 
in response to rIL-1 by BMDMs (Figure 7D) or peritoneal macrophages (Figure 7E). However, all 
macrophages secreted pro-inflammatory cytokines when stimulated with LPS, the positive control. 
 
Figure 6: BMDM differentiation yields CD115+ macrophages in culture. 
Flow cytometry data showing CD115+ cells on Day 5 of BMDM differentiation with 15% L929 media. 
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In addition, we tested if LPS-priming the cells before rIL-1 treatment would lead to 
increased secretion of TNFα. With J2 macrophages, we saw a slight increase with IL-1β treatment 
but not IL-1α (Figure 8A). BMDMs did not show an increase in TNFα secretion in response to 
LPS priming followed by IL-1 stimulation (Figure 8B). These data indicate that LPS priming of 
the cells is unlikely to lead to a dramatic change in macrophage response to IL-1. 
Figure 7: Murine macrophages do not secrete IL-6 and TNFα when stimulated with rIL-1. 
(A-E) ELISA data showing IL-6 secretion (A) and TNFα secretion (B-E) after treatment as indicated for 5h 
(A-C) or 24h (D-E) by J2 macrophages (A-B), or BMDMs (C-D) or peritoneal macrophages (E). US = 
unstimulated. LPS = 1µg/ml, rIL-1 = 50ng/ml. (A, D, E n = 2; B-C n = 4). Data represents mean ± SEM, 
p=*<0.05, **<0.01. 
J2 5h J2 5h BMDMs 5h 
BMDMs 24h J2 24h 
 3.4. Murine BMDCs respond to treatment with rIL-1 
In addition to macrophages, we also investigated BMDCs to see if they would secrete IL-
6 in response to IL-1 treatment. We observed that there was some secretion of IL-6 when cells 
were stimulated with IL-1α or IL-1β (Figure 9) but this was at a lower level than the LPS positive 
control. This indicates that BMDCs are able to respond to stimulation with IL-1, especially IL-1β.  
Figure 9: Primary murine BMDCs secrete IL-6 when stimulated with rIL-1. 
ELISA data showing IL-6 secretion from BMDCs with treatment as indicated (24h) (n = 2). US = 
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Figure 8: LPS-priming of macrophages prior to treatment with rIL-1 did not lead to increased TNFα 
secretion. 
(A-B) ELISA data showing TNFα secretion from J2 macrophages (n = 2) (A) and BMDMs (n = 2) (B) after 
priming with LPS (5h) and treatment as indicated (24h). US = unstimulated. LPS = 1µg/ml, rIL-1 = 50ng/ml. 














3.5. Primary human monocytes and macrophages do not respond to treatment with rIL-
1  
Furthermore, we examined primary human macrophages and monocytes that have been 
shown to express IL-1R1 to see if stimulation with rIL-1 would lead to secretion of pro-
inflammatory cytokines. Similar to murine macrophages, both human monocytes and 
macrophages did not produce TNFα in response to rIL-1, in contrast to the LPS positive control 
(Figure 10).  
Figure 10: Human monocytes and macrophages do not secrete TNFα in response to treatment with rIL-1. 
(A-B) ELISA data showing TNFα secretion from primary human monocytes (n =2) (A) and macrophages (B) (n 
= 2) with treatment as indicated (24h). US = unstimulated. LPS = 1µg/ml, rIL-1 = 50ng/ml. Data represents 
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3.6. IL-1 signalling is not inhibited by IL-1R2 
 We explored the hypothesis that macrophages do not respond to IL-1 because IL-1R2 is 
inhibiting IL-1 binding to IL-1R1. To investigate, we tested Il1r2-/- BMDMs for TNFα secretion 
in response to IL-1 stimulation. There was no TNFα secretion after 5 hours (Figure 11A) or 24 
hours (Figure 11B) of rIL-1 treatment by the Il1r2-/- or WT cells, indicating that IL-1R2 is not 
responsible for inhibition of IL-1 signalling in macrophages. This is in disagreement with Shimizu 
et al. (2015), who reported that Il1r2-/- BMDMs secreted increased pro-inflammatory cytokines 
with rIL-1 stimulation. 
3.7.  IL-1 signalling is not inhibited by ST2 
Brint et al. (2004) reported that cytokine release by peritoneal macrophages after IL-1 
treatment was dramatically higher from St2-/- cells compared to WT cells, which did not secrete 
any cytokines in response to IL-1. We replicated this experiment in St2-/- cells but saw no increase 
in TNFα secretion when treated with rIL-1 by St2-/- BMDMs (Figure 12A) or St2-/- peritoneal 
macrophages (Figure 12B). We also did not see any expression of St2 in WT BMDMs via qPCR 
and this may explain the lack of an increase in IL-1 response from the knock-out cells (Figure 
Figure 11: Il1r2-/- BMDMs do not respond to treatment with rIL-1. 
(A-B) ELISA data showing TNFα secretion from WT BMDM and Il1r2-/- BMDMs after treatment as indicated 
for 5h (n = 2) (A) or 24h (n =2)  (B). US = unstimulated. LPS = 1µg/ml, rIL-1 = 50ng/ml. Data represents mean 
± SEM.  
5h 24h 
 55 
12C). This shows that IL-1 signalling through IL-1R1 in macrophages is not inhibited by the ST2 
receptor, in disagreement with Brint et al. (2004). 
3.8. IL-1 signalling is not inhibited due to a lack of IL-1RAcP  
IL-1RAcP is the coreceptor for IL-1R1 and is required for downstream signalling after IL-
1 binding to IL-1R1. We hypothesised that insufficient IL-1RAcP may lead to inhibition of IL-1 
signalling by macrophages. We stained for IL-1RAcP in BMDMs and in cells that are known to 
respond to IL-1 stimulation as a positive control, i.e. HeLa cells and murine fibroblasts. None of 
these cell types showed any positive staining, indicating that we would need another method to 
determine IL-1RAcP levels.   
IL-33 is a cytokine that signals through the ST2 receptor, which also uses IL-1RAcP as the 
coreceptor. Therefore, we treated macrophages with rIL-33 and/or LPS and measured TNFα 
release as an assay to indicate successful signalling through ST2 and IL-1RAcP interaction. When 
cells were treated with a combination of LPS and rIL-33, there was a large downregulation in 
TNFα secretion by J2 macrophages compared to LPS treatment alone (Figure 13A). BMDMs 
showed a similar decrease but to a lesser extent. This indicated that there must be functional IL-
1RAcP present within those cells. 
Figure 12: St2-/- BMDMs and peritoneal macrophages do not secrete TNFα in response to treatment with 
rIL-1. 
(A-B) ELISA data showing TNFα secretion from St2-/- BMDMs (n = 2) (A) or from WT and St2-/- peritoneal 
macrophages (n =2) (B), after treatment as indicated for 24h. qPCR data showing St2 mRNA expression in 
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To see if the lack of response to IL-1 by macrophages is due to insufficient IL-1RAcP, we 
transfected J2 macrophages with an IL-1RAcP expression plasmid and treated cells with rIL-1. 
IL-1RAcP overexpression did not lead to increased TNFα secretion by macrophages (Figure 13B), 
indicating that insufficient IL-1RAcP is not the reason for the lack of response to IL-1 treatment. 
The GFP control showed 83% transfection efficiency (Figure 13C) but we were unable to check if 
this corresponded in protein expression due to the lack of a working antibody in the market.  
Figure 13: Macrophages have functional IL-1RAcP and overexpression of IL-1RAcP does not increase 
macrophage secretion of TNFα in response to rIL-1. 
(A-B) ELISA data showing TNFα secretion by J2 macrophages and BMDMs treated as indicated (5h) (n 
=1) (A), or by J2 macrophages when transfected with empty vector or IL-1RAcP-containing pCDNA3,  
followed by treatment as indicated (5h) (n =4) (B). Flow cytometry data showing transfection efficiency 
of the empty pcDNA3 vector vs. pGFP vector (n =4) (C). US = unstimulated. LPS = 1µg/ml, rIL-1 = 50ng/ml. 
Data represents mean ± SEM.  
5h 5h 
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3.9. J2 macrophages, BMDMs and BMDCs do not express IL-1R1 
We verified specificity of our murine IL-1R1 antibody with WT and Il1r1-/- primary mouse 
fibroblast. This showed a complete loss of staining in the knock-out cells, indicating that the 
antibody was staining specifically for IL-1R1 (Figure 14A). In our pilot studies, we stained for IL-
1R1 on murine BMDMs and saw that there was IL-1R1 present (Figure 14B).  
To look into this further, we stained J2 macrophages for IL-1R1 whilst also incorporating 
a permeability. There was high IL-1R1 staining in the permeabilised population (top panel, Figure 
15A) compared to the intact population, which did not stain positively for IL-1R1 (bottom panel, 
Figure 15A), indicating non-specific staining in the permeabilised cell population. Here we see 
that a permeability dye is necessary when staining for cell surface proteins as it ensures that we 
are getting specific staining of the target protein. Overall, we did not see any IL-1R1 expression 
on J2 macrophages when gated on the intact cells (Figure 15B). Due to this, we repeated BMDM 
IL-1R1 staining with the permeability dye. Intact BMDMs did not express IL-1R1 (Figure 15C), 
nor did BMDCs (Figure 15D), despite previously showing that BMDCs were able to respond to 
rIL-1. This indicates that there may be insufficient IL-1R1 expression by BMDMs to respond to 
rIL-1 treatment. BMDCs secreted around 200pg/ml of IL-6 when treated with rIL-1, which is quite 
low in comparison to secretion in the ng/ml range from HeLa cells. Thus, it may be that there is a 
Figure 14: Pilot data showing putative IL-1R1 expressed on BMDMs. 
Flow cytometry data showing IL-1R1 expression on WT and Il1r1-/- primary murine fibroblasts with 
antibody dilution as indicated (n = 1) (A). Flow cytometry plot showing IL-1R1 expression on BMDMs (n= 






































Figure 15: Mouse macrophages and BMDCs do not express detectable levels of IL-1R1.  
Flow cytometry plots showing J2 macrophages stained with a permeability dye followed by IL-1R1+ cells in 
the permeable (top) and intact (bottom) gates (n = 5) (A). Flow cytometry data showing IL-1R1 expression 
on intact cells for J2 macrophages (n =2) (MFI = -LPS 2001, +LPS 2234) (B), BMDMs (n = 3) (MFI = -LPS 2316, 
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3.10. Human monocytes and HeLa cells express IL-1R1, but human macrophages 
do not 
We examined primary human monocytes, macrophages and HeLa cells for IL-1R1, 
specifically gated on the intact population. We saw that monocytes expressed some IL-1R1 on the 
cell surface, which increased with LPS stimulation up to around 17% (Figure 16A). However, 
human macrophages had less than 5% expression and this did not change with LPS stimulation 
(Figure 16B). Despite this, as previously shown, both human monocytes and macrophages do not 
respond to IL-1 treatment. HeLa cells are routinely used in our lab as a bioassay as they are known 
to secrete IL-6 in response to IL-1. We stained them for IL-1R1 as a positive control and observed 
around 30% of IL-1R1 expression on LPS-stimulated and non-stimulated samples, correlating with 
the ability of HeLa cells to respond to IL-1 (Figure 16C). This level of expression on HeLa cells 
was more than two-fold higher than that observed on human monocytes.  
3.11. Murine macrophages transfected with IL-1R1 may respond to rIL-1 
Having seen that there was no IL-1R1 on the surface of macrophages, we tested if 
overexpressing IL-1R1 would lead to a response to rIL-1. We transfected cells with an IL-1R1-
expression vector before rIL-1 treatment and assayed for TNFα release. In J2 macrophages there 
appears that there may be a trend towards a small increase in IL-1-induced TNFα production after 
Figure 16: Primary human monocytes and HeLa cells express IL-1R1 but primary human macrophages 
do not. 
(A-C) Flow cytometry data showing IL-1R1 expression ±LPS treatment (5h) on intact primary human 
monocytes (n =2) (A), human macrophages (n =2) (B), or HeLa cells (n =2) (C).  LPS = 1µg/ml. Data 
represents mean ±SEM. 
Human Monocytes 5h Human Macrophages 5h HeLa 5h 
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IL-1R1 transfection, compared to untransfected cells (Figure 17A). However, the difference did 
not achieve significance, despite seeing an increase in IL-1R1 expression on J2 macrophages of 
12% (Figure 17B). In BMDMs, there seemed to be a small increase of response to IL-1α treatment 
by IL-1R1-transfected-cells compared to its untreated control and this level was also higher than 
that seen by cells transfected with the empty vector (Figure 17C), but the samples size for these 
experiments require expanding to verify this trend. These data indicate that a reason why 
macrophages do not respond to IL-1 may be because they do not have enough expression of IL-
1R1 on the cell surface.  
  
Figure 17: Overexpression of IL-1R1 shows a trend towards an increase in IL-1 response by murine 
macrophages. 
J2 macrophages (n = 4) (A, B) and BMDMs (n = 2) (C) were transfected with excess IL-1R1 or the empty 
pcDNA3 vector and treated as indicated (5h). ELISA data showing TNFα secretion from J2 macrophages 
after transfection (A). Flow cytometry plot showing IL-1R1 expression on J2 macrophages after 
transfection (B). ELISA data showing TNFα secretion from BMDMs after transfection (C). US = 





A B CJ2 5h J2 5h BMDMs 5h 
 61 
3.12. Discussion 
It is generally accepted that IL-1R1 is expressed on many different immune cell types in 
order to respond to IL-1 secreted or released by neighbouring cells and lead to an inflammatory 
cascade. Preliminary experiments in our lab showed that there was IL-1R1 expression on murine 
macrophages and this has been reported by several other groups (Garlanda, Dinarello, et al., 2013; 
Groß et al., 2012; Song et al., 2018). There have also been assumptions made in the literature that 
macrophages, neutrophils and monocytes respond to IL-1 (Sims et al., 2010). However, we did not 
see secretion of pro-inflammatory cytokines by murine macrophages treated with rIL-1. This 
prompted us to look closer as we hypothesised that there may be another mechanism that inhibits 
IL-1 signalling that has not been reported. 
We examined ST2 as a possible explanation for the inhibition of IL-1 signalling through 
the sequestration of proteins required for IL-1 signalling but this did not appear to be the case. We 
were unable to replicate the results seen by Brint et al. (2004) where there was an increase in pro-
inflammatory cytokine secretion by St2-/- peritoneal macrophages treated with rIL-1 compared to 
WT. This is due to the lack of expression of St2 in WT cells and therefore its knock-out is unlikely 
to yield different results. Brint et al. (2004) also reported that ST2 can inhibit TLR4 signalling and 
we observed this as there was a higher amount of pro-inflammatory cytokine secreted by St2-/- 
macrophages compared to WT in response to LPS stimulation (Figure 12B). Interestingly, soluble 
ST2 treatment has been reported to downregulate pro-inflammatory cytokine secretion, including 
TNFα, IL-6 and IL-1α by LPS-treated alveolar macrophages (Oshikawa et al., 2002), contributing 
to the hypothesis that ST2 is inhibitory on TLR4 signalling. This discrepancy between our findings 
on macrophage response to rIL-1 may be due to the difference in culture length as they carried out 
stimulations for 48-hour time periods whereas we stimulated our macrophages for 24 hours. We 
did not stimulate cells for 48 hours because we observed that there was cellular detachment and 
general yellowing of the media, which indicated to us that the cells were stressed and prolonging 
the stimulation time point in spite of this would introduce more artificiality into the experiment.  
Macrophages can be polarised into M1 and M2 stages, where M1 is the classical pro-
inflammatory state and M2 is the anti-inflammatory state that leads to TH2 responses (macrophage 
polarisation and its characteristics is elaborated on in later in Section 7.1). IL-33 is the cytokine 
that binds and signals through ST2 and this leads to an increase in Type 2 cytokines like IL-5 and 
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IL-13 to enhance TH2 responses. It may be that our macrophages do not express ST2 because they 
are not in the M2-polarised state. As ST2 has a function in promoting anti-inflammatory Type 2 
responses, it would make sense that IL-1 pro-inflammatory signalling is inhibited by ST2 in order 
to perpetuate the Type 2 phenotype. It may be interesting to see if polarisation of macrophages 
followed by treatment with rIL-1 can lead to differential responses between the macrophage 
subsets.  
We show that it is important to use a permeability stain to ensure that expression of IL-1R1 
is only detected on the plasma membrane. This is important because permeabilised and dead or 
dying cells dying have a higher level of autofluorescence and can non-specifically bind antibodies. 
Indeed, our initial stain for IL-1R1 without a permeability gate indicated IL-1R1 expression on 
macrophages, spurring experiments to identify why macrophages do not respond to IL-1. 
However, upon examination of the intact cell population, IL-1R1 staining was absent in murine 
and human macrophages. This demonstrates the importance of using a cell permeability gate when 
staining for any cell surface protein- a practice that is commonly overlooked. This is inconsistent 
with the RNA-seq data that we obtained (Figure 5), where human macrophages express Il1r1 
RNA. In contrast, cells that are known to respond strongly to IL-1 stimulation including murine 
fibroblasts and HeLa cells express higher levels of IL-1R1 on the cell membrane.  
Out of the examined cell types, only BMDCs released IL-6 in response to rIL-1, but this is 
quite low at around 200pg/ml. In comparison, rIL-1 typically elicits IL-6 secretion in ng/ml range 
from HeLa cells. It may be that in order to produce a large response to IL-1 stimulation, a threshold 
of IL-1R1 expression is required, perhaps above 30%. Transfection of IL-1R1 into J2 macrophages 
and BMDMs showed a trend towards an increase in TNFα secretion in response to IL-1 
stimulation. However, the transfections led to only about 12% of cells expressing IL-1R1 and this 
may explain why the level of TNFα secretion is still low in comparison to empty vector 
transfections. Overexpression of vectors in primary macrophages has a reputation for being more 
difficult. Indeed, immortalised J2 murine macrophages displayed less cell death and a high 
transfection efficiency compared to the primary BMDMs.  
In our experiments, the BMDMs seem to contain the machinery necessary to produce pro-
inflammatory cytokines (seen when stimulated with LPS) and they also contain a functional IL-
1RAcP co-receptor. However, they do not seem to express IL-1R1 necessary for successful IL-1 
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signalling. An explanation for why macrophages do not express IL-1R1 may be because of their 
involvement in inflammasome activation. The inflammasome is a complex that after receiving the 
appropriate stimulation, can become activated and lead to caspase-1 maturation and subsequent 
IL-1β and IL-18 processing and release. IL-1β is a potent inflammatory cytokine that can lead to 
the production of a large number of cytokines, inflammatory mediators and chemokines and 
potentially cause much tissue destruction. It may be that the reason why IL-1R1 is not expressed 
by macrophages is because it could lead to a lot of tissue damage to the local environment, in 
addition to damage that can be caused by inflammasome activation so perhaps this lack of IL-1R1 
is a way of limiting destruction. Another explanation for the lack of IL-1R1 expression may be 
that our BMDMs require polarisation to M1 in order upregulate IL-1R1 expression and 
accommodate this pro-inflammatory phenotype. M1 macrophages have been suggested to express 
IL-1R1 on the cell surface (Tugal et al., 2013) and it may be interesting to confirm if there would 
be IL-1R1 expression after M1 polarisation on macrophages and if the treatment of the polarised 
macrophages with rIL-1 can lead to even more pro-inflammatory cytokine secretion. 
Il1r2-/- BMDMs treated with rIL-1 also did not show an increase in pro-inflammatory 
cytokine secretion compared to WT BMDMs. It would be interesting to know if there is Il1r2 
expression within these macrophages or protein expression on the membrane and this will be 
discussed further in the upcoming sections.  
Macrophages have a role in patrolling for pathogens and DAMPs in order to lead to an 
inflammatory response to clear the invading infection. It has long been assumed that macrophages 
express IL-1R1 likely to perpetuate this inflammatory loop by IL-1 signalling. However, we do 
not know if pathogenic stimuli resulting in IL-1 secretion can lead to autocrine/paracrine IL-1 
signalling in long term cultures beyond 24 hours or in vivo and this would be interesting to 
investigate.  
There are limitations to this chapter that requires further investigation, including increasing 
n numbers for experiments. Transfecting IL-1R1 into macrophages indicated that this may lead to 
an increase in IL-1 response of the macrophages. However, this requires a larger sample size in 






















Results: Cell surface IL-1α  
4. Optimising csIL-1α staining on macrophages 
4.1. Introduction 
IL-1α is a potent inflammatory cytokine and in its precursor form, IL-1α has low level 
bioactivity at around 33kDa and this can be cleaved by proteases to a 17kDa mature protein that 
has more bioactivity. IL-1α is expressed constitutively in structural cells like epithelial cells and 
fibroblasts and its expression in increased with cellular stress and stimulation. Cell surface IL-1α 
(csIL-1α) is the membrane-bound form of IL-1α and this was first described in 1985 by Kurt-Jones 
et al. where fixed murine peritoneal macrophages were shown to stimulate thymocyte 
proliferation. csIL-1α has since been described on macrophages, monocytes, BMDCs, B cells and 
on fibroblasts and epithelial cells. In immune cells, csIL-1α is typically not expressed until the 
cells are stimulated. Previous stimuli that have been shown to upregulate csIL-1α are LPS 
(Fettelschoss et al., 2011), peptone and  Listeria monocytogenes  (Kurt-Jones et al., 1985).  
Despite IL-1α being a well-studied cytokine, the cell surface form of IL-1α is not well 
understood. Since its discovery there have been reports that refute the existence of a cell surface 
form of IL-1α, suggesting instead that leaked intracellular IL-1α was being falsely identified as 
csIL-1α (Bailly et al., 1990; Minnich-Carruth et al., 1989). Due to IL-1α being expressed 
intracellularly, it is necessary to make a clear distinction between IL-1α found within the cell and 
that on the outer surface of the plasma membrane. In early studies examining csIL-1α, fixation 
was used to fix csIL-1α epitopes in place for subsequent detection, and this fixation was also 
assumed to prevent leakage of intracellular IL-1α (Kurt-Jones et al., 1985). The use of fixation is 
a key area of contention in the field, as it has been described to cause significant leakage of IL-1α 
from the cell, even after 24h of fixation and multiple washes (Minnich-Carruth et al., 1989). 
Fixation was a necessary step as csIL-1α detection used IL-1 induced thymocyte proliferation as a 
bioassay to IL-1 activity and thus csIL-1α presence. We decided to identify csIL-1α via flow 
cytometry as this is a direct way of detecting csIL-1α.  
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We will examine the effect of fixation on the cell membrane integrity of macrophages and 
we will also investigate the effects of fixation on csIL-1α levels. This is important because the use 
of fixation has been a divisive issue and we would like to understand, by directly detecting IL-1α 
on the membrane, if fixation leads to a difference in IL-1α detection. In addition to that, we would 
also like to understand if there is IL-1α leakage from within the cell into the supernatant as a result 
of fixation. As seen in Section 3.9, autofluorescence and non-specific binding of the antibody to 
dead cells can lead to false positive staining. Thus, the use of a cell permeability dye would be 
vital to discriminate between IL-1α expressed on the membrane of intact cells and non-specific 
staining – a measure not used in any studies that report csIL-1α expression in the literature. It has 
also been reported that trypsin has the ability to liberate csIL-1α from the membrane (Kobayashi 
et al., 1990; Matsushima, Taguchi, et al., 1986; Niki et al., 2004), indicating its sensitivity to 
digestion. This suggests that csIL-1α is sensitive to protease cleavage and measures must be taken 
when culturing and detaching cells to minimise loss of cell surface proteins. 
It is important to clarify the authenticity of csIL-1α as it has been recently reported to be 
crucial for the IL-6 and IL-8 secretion associated with senescence (Orjalo et al., 2009) but it is not 
understood how this occurs. We also do not understand how csIL-1α expression affects other 
immune cells and how this would contribute to inflammatory disorders, revealing an interesting 




4.2. Fixation with formaldehyde leads to increased IL-1α staining 
Macrophages are the main cell type reported to express csIL-1α (Brody et al., 1989; Conlon 
et al., 1987; Fettelschoss et al., 2011). We investigated if we could identify csIL-1α on J2 
macrophages and primary murine BMDMs, and if formaldehyde fixation altered the levels 
detected. Cells were treated with and without LPS before fixation with 2% formaldehyde and 
subsequently stained for IL-1α with a fluorescently labelled antibody. This showed high levels of 
staining on fixed J2 macrophages compared to non-fixed cells, both with and without LPS (Figure 
18A). This was an unexpectedly high level of IL-1α staining, which is contradictory to what has 
been described in the literature where fixation did not affect the level of csIL-1α. 
 We did not see such a dramatic increase in IL-1α staining on fixed BMDMs, although 
there was increased IL-1α detection with fixation in the LPS-treated samples (Figure 18B). This 
suggested that fixation can confound IL-1α detection.    
4.3. The use of a permeability stain is necessary to investigate true csIL-1α 
 We incorporated the permeability dye into our staining procedure and this allowed us to 
specifically gate on live, intact macrophage populations and measure IL-1α staining on these cells 
Figure 18: Murine macrophages express high levels of putative csIL-1α when fixed with formaldehyde.  
(A-B) Flow cytometry data showing csIL-1α expression ±LPS (5h) ±fixation (2% formaldehyde 15 mins RT) 
on J2 macrophages (n =4) (MFI = -LPS – Fix 1824, -LPS +Fix 3081, +LPS -Fix 1701, +LPS +Fix 2954) (A), or 
primary BMDMs (n =1) (MFI = -LPS -Fix 2486, -LPS +Fix 2694, +LPS -Fix 2420, +LPS +Fix 3123) (B). LPS = 
1µg/ml. The macrophage population was gated on and putative csIL-1α levels were derived from IL-1α 
staining observed in this population. Data represents mean ±SEM. 
J2 5h BMDMs 5h 
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only. This showed a distinct population of cells that have lost membrane integrity whilst also 
staining positively for IL-1α (top panel, Figure 19A). In contrast, IL-1α levels are much lower if 
gated on the intact population (bottom panel, Figure 19A), indicating that without a viability dye 
icIL-1α can easily be falsely reported as csIL-1α. We also utilised propidium iodide (PI) staining 
(a fluorescent stain that binds to DNA) to evaluate cell viability and found that it produced similar 
levels of staining as the L/D permeability dye (Figure 19B), confirming that there is false positive 
staining in the permeable population. In addition, we investigated the viability of cells after 
treatment with increasing concentrations of fixative. This showed that increasing concentrations 
of formaldehyde led to significantly increased permeabilised cells (Figure 19C).  
Figure 19:  The use of a cell viability stain is necessary to ensure staining of csIL-1α on intact cells only. 
(A-B) Flow cytometry plots showing untreated primary BMDMs stained with an anti-IL-1α antibody and 
gated into populations positive and negative for cell permeabilisation (n =7) (A), or stained with propidium 
iodide or L/D (n =1) (B). Flow cytometry data showing level of permeabilisation in BMDMs treated with 
fixative at the concentrations indicated (15 mins RT) (n = 7) (C). Data represents mean ±SEM, 
p=****<0.0001. 
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 To illustrate the inaccuracy of staining for csIL-1α without a viability dye, we stained 
BMDMs with an IL-1α antibody alone. These showed a high and variable level of detection with 
different concentrations of fixative (Figure 20A). In contrast, csIL-1α levels of intact cells (using 
the permeability stain) were seen to drop with increasing concentrations of fixative (Figure 20B). 
Furthermore, there was a significant increase in leakage of soluble IL-1α into supernatants from 
fixed BMDMs compared to non-fixed (Figure 20C). Therefore, the use of a permeability stain with 
flow cytometry is essential to ensure detection of csIL-1α on intact, live cells as opposed to 
intracellular or non-specific staining. Similarly, formaldehyde fixation cannot be used to 
investigate csIL-1α as it permeabilises cells. 
4.4. Accutase detaches adherent BMDMs without disrupting csIL-1α levels 
BMDMs are notoriously difficult to remove from tissue culture (TC)-treated surfaces. We 
failed to detach BMDMs from TC-treated plates using cold EDTA, accutase and trypsin.  Physical 
scraping removed the cells from the plate, but this damages cells and would likely lead to loss of 
plasma membrane integrity. Therefore, we plated macrophages on non-TC treated plates, allowed 
for cell differentiation and then compared accutase and trypsin for macrophage detachment. 
Trypsin is a protease that cleaves on the C-terminus of lysine or arginine residues and has been 
reported to cleave pro-IL-1α to the mature form (Kobayashi et al., 1990). Accutase is described as 
a gentle cell dissociation solution that contains collagenolytic and proteolytic enzymes. We 
Figure 20: Formaldehyde fixation of cells leads to cell permeabilisation and leakage of IL-1α.  
(A, B) Flow cytometry data showing primary LPS-treated (1µg/ml) BMDMs with fixation as indicated 
(15mins RT) stained for IL-1α alone (n = 4) (A), or for csIL-1α with the L/D dye, gated on the viable 
population (n =4) (B). (C) ELISA data showing IL-1α level in the supernatant of BMDMs treated ±LPS and 
±1% formaldehyde fixation (n =5). Data represents mean ±SEM, p=*<0.05, **<0.01. 
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observed that macrophage detachment with accutase retained a higher amount of csIL-1α 
compared to using trypsin (Figure 21), and thus we decided to only use accutase to dissociate our 
cells for experiments. 
4.5. Validation of anti-IL-1α antibodies 
To verify the specificity of the monoclonal ALF161 PE-conjugated IL-1α antibody we 
compared IL-1α levels between WT and Il1α-/- BMDMs. This showed variable levels of staining 
in the WT and some non-specificity in the Il1α -/- BMDMs (Figure 22A). We also tested different 








Figure 21: Macrophage detachment using accutase allows for more csIL-1α retained compared to using 
trypsin. 
Flow cytometry data showing csIL-1α expression on LPS-treated BMDMs (24h) after detachment with 
accutase (10 mins RT) or trypsin (5 mins 37°C) (n = 1). Data represents mean ±SEM. 
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 Thus, we tested an alternative biotinylated IL-1α antibody (clone BL1a-89) using 
Streptavidin-PE as the detection reagent. There was still some non-specific staining of Il1α-/- 
BMDMs with 1:200 and 1:250 dilutions when stained at room temperature (Figure 23A). 
However, using the antibody at 1:300 on ice removed the non-specific staining (Figure 23B). With 
these staining conditions, a detectable level of csIL-1α on WT BMDMs is observed whilst 
maintaining low non-specific staining both within and on the cell surface of Il1α-/- BMDMs. Due 
to this, we carried out all future experiments to investigate csIL-1α using the BL1a-89 antibody 
and staining on ice. 
We noticed some discrepancy between batches of BL1a-89 antibodies and the levels of IL-
1α staining (Figure 23C). For most of the project, the B215458 lot was used, until its 
discontinuation. The next lot, B188306, produced suspiciously high levels of csIL-1α staining, 
which turned out to be non-specific upon staining Il1α-/- BMDMs (Figure 23C). In light of this, we 
did not use this antibody and excluded all data from analyses. Another lot, B275973, showed 
specific csIL-1α (Figure 23C) and icIL-1α (Figure 23D) staining similar to the B215458 lot. Thus, 
with any change of antibody lots we verified specificity with Il1α-/- BMDMs before using them. 
Figure 22: ALF161 anti-IL-1α antibody shows variable levels of staining and may be non-specific. 
(A, B) Flow cytometry data showing IL-1α expression ±LPS (1µg/ml). in WT and Il1α-/- BMDMs stained with 
the ALF161-PE antibody (A), or with the unconjugated ALF161 antibody in dilutions indicated and a 
secondary (B). The ALF-PE antibody detects the p17 cytokine portion of IL-1α. Data represents mean 
±SEM. 
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4.6. LPS from Escherichia Coli 0111:B4 produces the highest level of csIL-1α expression 
We tested several LPS preparations to see which would yield the highest amount of csIL-
1α expression. Ultra-pure LPS is produced by a re-purification process via a phenol-TEA-DOC 
protocol by the manufacturer, producing LPS that strictly activates only the TLR4 pathway. The 
standard LPS preparation is less clean and may trigger TLR2 and TLR4 activation and LPS 
0111:B4 was the least pure due to a less rigorous purification process and likely contains TLR2 
and TLR4 agonists as well. Of the three, LPS 0111:B4 produced the most csIL-1α (Figure 24A), 
possibly indicating that TLR2 and TLR4 activation can stimulate more production of csIL-1α than 
TLR4 alone. As a precaution, we also confirmed that none of the three LPS preparations caused 
non-specific staining within the Il1α-/- BMDMs (Figure 24B).  
Figure 23: Some lots of the BL1a-89 antibody show non-specific 
staining and all lots used were verified with Il1α-/- cells.  
Flow cytometry data showing csIL-1α expression on WT and Il1α-/- 
BMDMs stained with the BL1a-89 antibody ±LPS (1µg/ml) in 
dilutions indicated at RT (n = 1-5) (A), or at 1:300 on ice ±perm 
+LPS (n = 3-5) (B). Flow cytometry data showing csIL-1α expression 
on WT and Il1α-/- BMDMs stained with different lots of BL1a-89 
antibody at 1:300  on ice -perm (n = 2-5) (C),  or +perm (n = 3) (D). 
The ALF-PE antibody detects the p17 cytokine portion of IL-1α. 
Data represents mean ±SEM. 
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Figure 24: LPS 0111:B4 produces a larger csIL-1α signal compared to ultra-pure and standard LPS 
preparations.  
(A-B) Flow cytometry data showing csIL-1α expression on BMDMs when treated with ultra-pure (UP), 
standard and 0111:B4 LPS preparations (1µg/ml 24h) (n = 1-3) (A), or ±permeabilisation in WT and Il1α-/- 
BMDMs (n =1) (B). Data represents mean ±SEM. 
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4.7. Discussion 
Early experiments that describe csIL-1α used a thymocyte proliferation bioassay to 
indirectly detect IL-1α. The use of fixation was deemed necessary to crosslink the epitopes on the 
cell membrane in place to allow for detection of csIL-1α (Kurt-Jones et al., 1985). We show that 
fixation can lead to increased cell permeability and a viability dye to exclude dead or dying cell 
populations is necessary to detect csIL-1α on live intact cells. Dead or dying cells can bind to 
monoclonal antibodies non-specifically and cause false detection of the target protein (Perfetto et 
al., 2006). Interestingly, the authors have also described that a class of permeability dyes called 
amine reactive viability dyes are more accurate and reproducible than DNA intercalating dyes like 
PI and the permeability dye that we use in our experiments is reactive to amines. Perfetto et al. 
(2006) postulate that the amine reactive viability dyes can enter cells that have damaged plasma 
membranes and bind to amine groups in the cytoplasmic compartment and this is more effective 
because conventional DNA dyes can leak out of the cells and cause the loss of signal.  
Kurt-Jones et al. (1985) carried out experiments to investigate csIL-1α by fixing peritoneal 
macrophages with 1% formaldehyde followed by a 24h incubation prior to the IL-1 assay. They 
show that the macrophages pulsed with Listeria and fixed followed by culturing with T cells led 
to increased T cell proliferation, and incubation with an anti-IL-1 antibody decreased this level. 
Both IL-1α and IL-1β can lead to thymocyte activation and proliferation (Carding et al., 1991; 
Zlotnik et al., 1995) and treatment of cells with Listeria can also lead to increased IL-1β (Lopez-
Castejon et al., 2011). It may be that the increase in T cell proliferation seen as a result of 
incubation with those macrophages by Kurt-Jones et al. (1985) is due to both IL-1α and IL-1β 
stimulation, not specifically IL-1α. This illustrates the importance of directly detecting csIL-1α as 
opposed to inferring its effects through a bioassay. Through developing an assay with a robust 
protocol to examine csIL-1α, we can now explore factors that affect csIL-1α expression. 
Macrophages are APCs that function to phagocytose invading pathogens and express 
pathogenic peptide on their MHCII molecules located in the plasma membrane. This complex on 
the macrophage membrane is presented to CD4+ T cells and leads to T cell stimulation and 
proliferation (Mantegazza et al., 2013). Kurt-Jones et al. (1985) report that incubation of 
membranes purified from Listeria-pulsed macrophages with T cells led to increased T cell 
proliferation. It is likely that the MHC II complexes with Listeria peptide presented on 
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macrophages is causing this increase in T cell proliferation as opposed to this being a strictly csIL-
1α effect.  
Kurt-Jones et al. (1985) also reported that fixed and non-fixed membranes of Listeria-
pulsed macrophages showed similar levels of T cell proliferation and concluded that fixation did 
not have an effect on csIL-1α levels. The authors also postulate that there is no soluble IL-1α 
leaking from the cells 24h after fixation. However, it has been reported that there is high IL-1α 
levels detected in the supernatants of fixed peritoneal macrophages (Minnich-Carruth et al., 1989), 
a finding that we confirm with our experiments. However, this casts doubt on the existence of 
csIL-1α, but we report that csIL-1α is a real phenomenon detected on intact macrophages and this 
is induced by TLR4 signalling.  
 A fine balance needs to be struck between measuring detectable levels of csIL-1α whilst 
preventing non-specific staining. Hence, we tried many different conditions and different 
antibodies available to achieve this. Staining temperature, antibody dilutions and antibody clones 
were all altered in order to determine the optimum staining conditions. Using a 1:300 dilution of 
the biotinylated antibody and staining at 4°C produced specific csIL-1α staining. In addition, we 
show that trypsin can decrease levels of csIL-1α and show that accutase dissociates cells from non-
TC-treated surfaces without removing csIL-1α from the membrane. csIL-1α is upregulated by 
TLR4 ligation, which requires further investigation, e.g. to determine if other TLRs are involved 
in this process. Interestingly, it was reported that csIL-1α is induced before secreted IL-1α and 
suggested to persist for longer than secreted IL-1α, this hints at csIL-1α being a precursor to 
secreted IL-1α, a hypothesis that will be discussed further in the following sections. 
 There are limitations to this chapter, the effect of accutase and trypsin on csIL-1α can be 
explored further as this was only carried out once. More n numbers can be added to find out if this 
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5. IL-1α is on the cellular membrane in its 33kDa form and can be cleaved off by thrombin  
5.1. Introduction 
TLR signalling is important in innate immunity as it is required to recognise PAMPs 
derived from pathogens. The cytoplasmic domain of TLRs are similar to that found on the IL-1 
receptor family members, and are called TIR domains (Takeda et al., 2005). TIR domains can 
interact with other TIR domains to form protein scaffolds that allow for protein complexes to 
assemble as part of the TLR signalling (Ve et al., 2015). When PAMPs and DAMPs bind to the 
TLR, adaptor proteins that contain TIR domains are recruited and this includes MyD88 and TRIF 
proteins. This leads to the activation of NF-κB, interferon-regulatory factor (IRF) members or 
MAP kinases, which instigates the secretion of chemokines and cytokines and subsequent immune 
responses (Kawasaki et al., 2014). TLR activation can lead to the secretion of cytokines like IL-1, 
IL-6, IL-12, IL-18 and TNFα (Moynagh, 2005). 
TLRs can be found within the cell or on the cell surface and these are typically expressed 
by DCs, macrophages, epithelial cells and fibroblasts (Kawasaki et al., 2014). Extracellular TLRs 
can bind to microbial lipoproteins, proteins and lipids whereas intracellular TLRs ligate bacterial 
and viral nucleic acids (Kawasaki et al., 2014). LPS, which ligates to TLR4, is known to induce 
IL-1α expression and we have shown it may increase csIL-1α levels. Thus, it would be interesting 
to learn if TLR4 is the only receptor that can lead to csIL-1α upregulation. In addition, TLR2 has 
also been reported in the literature to increase csIL-1α expression (Kurt-Jones et al., 1985). 
IL-1α is not typically found in healthy circulation, but can be released from dying cells to 
activate pro-inflammatory responses. IL-1α, like IL-1β, IL-33 and IL-18, is not secreted through 
the conventional Golgi-endoplasmic reticulum pathway, and not much is known about how it is 
secreted. This is due to a lack of a leader sequence to direct them through the conventional 
secretory pathway. It has been suggested that IL-1 is produced in free ribosomes associated with 
the cytoskeletal structure (Stevenson et al., 1992). Stevenson et al. (1992) also postulated that the 
distribution of IL-1 in the intracellular compartment may be influenced by the post-translational 
modifications imposed onto IL-1, including glycosylation (with mannose molecules) (Brody et al., 
1989) and phosphorylation (Kobayashi et al., 1988).  
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It has been speculated that caspase-1 is involved in the secretion of IL-1 family members 
as inflammasome activation leads to secretion of IL-1 (Keller et al., 2008; Ogura et al., 2006). 
Caspase-1 is known to activate IL-1β and IL-18, leading to their release (Ogura et al., 2006) and 
caspase-1 itself requires processing in order to carry this out. IL-1α secretion has been described 
to be influenced by caspase-1, although this is not well-understood as the authors report this effect 
is not due to the proteolytic activity of the enzyme (Keller et al., 2008). Caspase-1 does not act on 
the precursor form of IL-1α directly but it has been seen that Casp1-/- monocytes had impaired IL-
1α release when stimulated with LPS despite containing icIL-1α (Keller et al., 2008; Kuida et al., 
1995). This was later found to be an effect of the Casp1 knock-out, which harboured a Casp11 
mutation, leading to the lack of detectable caspase-11 (Kayagaki et al., 2011). Caspase-11 is the 
murine enzyme that binds to LPS, leading to cell death (Huang et al., 2019). It has recently been 
discovered that caspase-11 is required for the secretion of IL-1α (Wiggins et al., 2019). It would 
also be interesting to see if caspase-11 has an effect on csIL-1α levels. Macrophages and 
keratinocytes also had impaired IL-1α release after siRNA-mediated knock-down of Casp1 and 
knock-downs of other inflammasome components like Asc and NALP3 also led to decreased IL-
1α secretion (Keller et al., 2008), linking IL-1α secretion to components of the inflammasome.  
Gasdermin D is a protein that is involved in pyroptosis and that is cleaved by caspase-1. 
This allows it to form pores in the cellular membrane for the passive and active secretion of IL-1β 
(Evavold et al., 2018; Kayagaki et al., 2015; Monteleone et al., 2018; Shi et al., 2015). The effects 
of gasdermin D on IL-1α have not been investigated and we do not know if gasdermin D is 
necessary for csIL-1α presentation. The connection between icIL-1α, csIL-1α and secreted IL-1α 
has not been explored in previous studies and it may be that these forms of IL-1α are from the 
same origin, cycling through different positions from its synthesis to being shuttled to the cell 
surface followed by secretion to the extracellular space. 
There are a number of enzymes that can cleave IL-1α into its mature form including 
calpain, granzyme B, elastase, chymase and more recently described, thrombin. Thrombin has 
been found to cleave pro-IL-1α at a conserved site and cleavage at this site is required for effective 
wound healing (Burzynski et al., 2019). It has been revealed that the serine residues of the IL-1α 
precursor are phosphorylated and that this may aid in its processing to the mature IL-1α cytokine 
(Kobayashi et al., 1988). IL-1α release has also been suggested to be due to an active membrane 
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shedding pathway or through passive leakage due to perturbation of the membrane (Stevenson et 
al., 1992). csIL-1α is found in its precursor form and it is not known how this is produced and what 
pathway it follows in order to be presented on the cell surface.  
In this chapter we aim to discover whether the ligation of other TLRs can lead to increased 
csIL-1α. We will also investigate any connection between intracellular IL-1α and csIL-1α and 
observe if csIL-1α can be cleaved from the cellular membrane by proteases. We will also identify 
if the csIL-1α cleaved from the membrane into the supernatant has bioactivity. 
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5.2. csIL-1α is not an artefact and its expression persists with sustained LPS stimulation 
Having established a stimulation and staining protocol that specifically identified csIL-1α, 
we stained macrophages for csIL-1α expression with and without LPS stimulation. LPS 
stimulation significantly increased csIL-1α on intact BMDMs, with levels ranging between 5% 
and 32% staining (Figure 25A). In addition, we also saw that csIL-1α levels persisted if LPS 
remained in culture over time, even at 48 hours after stimulation (Figure 25B). 
To see how long csIL-1α would remain on the surface after removal of LPS from the media, 
we treated BMDMs with an LPS overnight stimulation, washed and replaced with LPS-free media. 
We then took cells at 0, 1 and 3 hours and assayed for csIL-1α. This showed a small trend of csIL-
1α levels beginning to drop 3 hours after replacing the media (Figure 26), indicating that 
continuous stimulation may be required for csIL-1α to remain on the membrane. 
Figure 25: Macrophages express genuine csIL-1α, with its expression persisting after prolonged LPS 
stimulation. 
(A, B) Flow cytometry data showing csIL-1α expression on BMDMs ±LPS (1µg/ml) overnight stimulation (n 
= 19) (A), or over time as indicated (n = 1-6) (B). Data represents mean ±SEM. p =*<0.05, **<0.01, 
****<0.0001.  
 5.3. Agonists of TLR2 induce csIL-1α expression 
To identify if csIL-1α is induced by ligation of other TLRs besides TLR4, we treated 
BMDMs with agonists that target TLR1-9, at concentrations recommended by the manufacturer 
(InvivoGen) (Table 6). TLR3, 7 and 9 are endosomal receptors and the means by which the 
agonists are internalised are as follows: Poly (I:C), which targets TLR3, has a structure similar to 
dsRNA, which can bind to class A scavenger receptors and be internalised (Nguyen et al., 2018). 
The preparation of ssRNA40, which binds to TLR7, used in our experiments had been complexed 
with a cationic lipid to enable uptake into cells. CXCL14, which is constitutively expressed, acts 
as a carrier for CpG ODN uptake into cells and this leads to stimulation of TLR9 (Tanegashima et 







Figure 26: Sustained LPS stimulation may be required for csIL-1α to remain on the membrane.  
Flow cytometry data showing csIL-1α expression on BMDMs after LPS (1µg/ml) stimulation overnight, 
followed by washing and replacement with LPS-free media. Cells were harvested and stained at 
indicated timepoints after washing (n = 2). Data represents mean ±SEM.  
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In these experiments, we saw the highest expression of csIL-1α with LPS treatment (Figure 
27). In addition, we also saw csIL-1α expression induced by Pam3CSK4 and HKLM and modest 
expression by FSL-1 and ssRNA40. Pam3CSK4 activates TLR1/2 by mimicking bacterial 
lipoproteins, HKLM activates TLR2 whereas FSL-1 is a lipoprotein that targets TLR2 and 6. 
ssRNA40 is a single-stranded RNA and activates TLR7. These agonists lead to TLR ligation and 
subsequent NF-κB activation and seem to increase csIL-1α, although not to the extent that TLR4 
ligation with LPS can. To see if csIL-1α levels can increase with combinations of different TLR 
agonists, we combined LPS with PAM3CSK4 and/or HLKM but did not see increased csIL-1α 
compared to LPS alone (Figure 27). The finding that TLR2 activation can lead to increased csIL-
1α expression on BMDMs was previously alluded to by Kurt-Jones et al. (1985) who also used 
HKLM to stimulate macrophages. However, we find that TLR2-driven csIL-1α expression is not 




TLR targeted Location Ligand Final concentration 
1/2 Cell membrane Pam3CSK4 300ng/ml 
2 Cell membrane HKLM 108 cells/ml 
3 Endosome Poly (I:C) (HMW)/(LMW) 10µg/ml 
4 Cell membrane LPS  1µg/ml 
5 Cell membrane FLA-ST 1µg/ml 
6/2 Cell membrane FSL-1 1µg/ml 
7 Endosome ssRNA40 100ng/ml 
9 Endosome ODN1826 5µM 
Table 6: TLR ligands and concentrations used to treat BMDMs.  
HKLM: Heat-killed Listeria monocytogenes. FLA-ST: Flagellin from Salmonella typhimurium. ODN: 
oligonucleotides. 
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5.4. csIL-1α is synthesised de novo after LPS stimulation 
We treated BMDMs with LPS and the translation inhibitor emetine and examined its 
effects on csIL-1α levels after 4 and 24 hours of treatment. This showed less csIL-1α levels with 
emetine treatment at 4 hours, which reached significance at 24 hours (Figure 28A), indicating that 
csIL-1α expression is hindered when translation is inhibited. We also measured total IL-1α levels 
through western blotting and saw a decrease with emetine treatment (Figure 28B). As a positive 
control, LPS-treated BMDMs that secrete TNFα were treated with emetine, which showed a 
decrease in TNFα production when translation was inhibited (Figure 28C). These results indicate 






Figure 27: PAM3CSK4 and HKLM can induce csIL-1α expression. 
Flow cytometry data showing csIL-1α expression on BMDMs when treated with TLR1-9 agonists as 
indicated (ON 37°C). Concentrations of each TLR agonist used are described in Table 5 (n = 2-7). Data 
represents mean ±SEM. P=****<0.0001. 
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5.5. Dexamethasone decreases icIL-1α and csIL-1α  
Dexamethasone is a corticosteroid medication used to treat many inflammatory conditions. 
It has been shown to decrease IL-1α (Amano et al., 1993) and IL-1β (Knudsen et al., 1987) mRNA 
accumulation and release. Its effects on csIL-1α levels has not been examined so we treated 
BMDMs with increasing concentrations of dexamethasone, which showed a decrease in LPS-
induced csIL-1α levels (Figure 29A). Dexamethasone also decreased IL-1α mRNA expression 




Figure 28: The translation inhibitor emetine inhibits csIL-1α trafficking to the membrane. 
Flow cytometry data showing csIL-1α expression of LPS-treated (1µg/ml) BMDMs ±emetine (1nM) treatment 
after 4h (n = 3) or 24h (n = 4) (A). Western blot data showing IL-1α expression in BMDMs ±LPS ±Emetine 
(1nM) 24h (n = 1) (B). ELISA data showing TNFα secretion from BMDMs ±LPS ±Emetine (1nM) 4h (n = 4) (C). 
Data represents mean ±SEM, p=**<0.01. 













































































5.6. csIL-1α is in the 33kDa pro-form and when cleaved from the membrane, its substrate 
shows biological activity 
It has previously been demonstrated that csIL-1α is the pro-form (Kurt-Jones et al., 1985) 
and our lab has shown p33 IL-1α to be cleaved by thrombin (Burzynski et al., 2019). We treated 
BMDMs with thrombin and saw decreased csIL-1α (Figure 30A-B). We also measured the 
corresponding supernatant for IL-1α and saw a significant increase in soluble IL-1α in thrombin-
treated samples (Figure 30C). In addition, we treated murine fibroblasts with these supernatants 
(SNs) to measure bioactivity of the thrombin-cleaved csIL-1α. Murine fibroblasts have IL-1R1 on 
the cell surface, as shown previously, and thus respond to IL-1α by producing IL-6. We saw 
increased IL-6 secretion with thrombin-cleaved samples and these levels were decreased when an 
IL-1α neutralising antibody was added (Figure 30D). It is likely that the fibroblasts in this figure 
are responding to LPS as there is a level of IL-6 secreted from the samples containing LPS but not 
thrombin cleavage of csIL-1α. A positive control of recombinant IL-1α treatment led to increase 
IL-6 secretion of the fibroblasts and these levels also decrease with the addition of an IL-1α 
neutralising antibody. This indicates that csIL-1α is likely to be the 33kDa pro-form as it can be 
cleaved off by thrombin. Once cleaved, IL-1α that was on the cell surface can be detected in the 
SN and this IL-1α has bioactivity.  
Figure 29: Dexamethasone decreases csIL-1α and icIL-1α.  
Flow cytometry data showing csIL-1α expression on BMDMs treated ±dexamethasone (concentration as 
indicated) ±LPS (1µg/ml) (n = 3) (ON 37°C) (A). qPCR data showing IL-1α mRNA expression in BMDMs 
treated ±dexamethasone (100µM) ±LPS (n = 1) (ON 37°C) (B). Data represents mean ±SEM, p=*<0.05, 
**<0.01. 
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As IL-1α is also known to be cleaved by calpain, a calcium-dependent protease (Carruth et 
al., 1991; Kobayashi et al., 1990), we attempted to cleaved csIL-1α off BMDMs using it. We 
treated BMDMs with LPS followed by calpain and measured csIL-1α expression but did not see 


















































































































Figure 30: csIL-1α is the 33kDa pro-form and once 
cleaved from the membrane, its substrate shows 
bioactivity. 
(A-B) Flow cytometry data showing csIL-1α expression 
on LPS-treated (1µg/ml ON) BMDMs ±thrombin at 
0.01U/µl (n = 7) (A) or 0.0025U/µl (n = 6) (30 mins RT) 
(B). (C, D) ELISA data showing IL-1α release in the SN 
of BMDMs treated ±LPS ±thrombin at concentrations 
indicated (U/µl) (n = 6) (30mins RT) (C), or IL-6 secreted 
by murine fibroblasts in response to ±LPS (1µg/ml ON) 
±thrombin-treated (0.01U/µl 30 mins RT) BMDM SN 
(n= 7) (D). Data represents mean ±SEM, p=*<0.05, 
p=**<0.01, p=****<0.0001. 
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Granzyme B is a serine protease that has also been described to cleave IL-1α (Afonina et 
al., 2011), and thus we tested if it would cleave csIL-1α. Granzyme B treatment did not lead to 
loss of csIL-1α (Figure 32). This may be because the sites at which calpain and granzyme B cleave 
are hidden or obstructed due to the conformation that csIL-1α is in when tethered to the membrane.  
Figure 31: Calpain does not cleave csIL-1α off the membrane.  
Flow cytometry data showing csIL-1α expression on LPS-treated (1µg/ml ON) BMDMs after treatment 
±calpain (1h) as indicated (n = 3) (1h RT). Data represents mean ±SEM. 
Figure 32: Granzyme B does not cleave csIL-1α off the membrane.  
Flow cytometry data showing csIL-1α expression on LPS-treated (1µg/ml ON) BMDMs after treatment 






















5.7. Involvement of components of the inflammasome in csIL-1α expression 
IL-1 secretion is regulated by gasdermin D, which makes pores in the membrane necessary 
for IL-1 to travel through and be released from cells (Kayagaki et al., 2015; Shi et al., 2015). We 
wanted to explore the possibility that gasdermin D was involved in the presentation of csIL-1α. 
Thus, we measured csIL-1α expression on Gsdmd-/- BMDMs, which did not show a decrease in 
csIL-1α compared to the WT control (Figure 33A), implying that csIL-1α is unlikely to require 
gasdermin D to be presented on the membrane.  
Human caspase-5 and its murine orthologue caspase-11 has also been shown to cleave IL-
1α, leading to its release (Wiggins et al., 2019). We measured csIL-1α expression in Casp11-/- 
compared to WT BMDMs but did not see a large decrease in csIL-1α expression (Figure 33B). 
Activation of caspase-1 by inflammasomes leads to secretion of IL-1β and IL-18, both members 
of the IL-1 super family. Due to the mutation of Casp11 in Casp1-/- cells resulting in the lack of 
caspase-11 protein production, we tested csIL-1α level on Casp1-/-Casp11Tg (which expresses 
caspase-11) in comparison to WT BMDMs, and although our experiments were limited by samples 
size, we did not see a dramatic difference in csIL-1α expression in these preliminary studies 
(Figure 33C). Activators of the NLRP3 inflammasome have been seen to increase IL-1α secretion 
Figure 33: Genetic deficiency of inflammasome machinery does not strongly affect csIL-1α expression.  
(A-C) Flow cytometry data showing csIL-1α expression ±LPS (1µg/ml ON) treatment on WT BMDMs and 










































































(Groß et al., 2012). Thus, we treated BMDMs with MCC950, an inhibitor of the NLRP3 
inflammasome, but did not see any decrease in csIL-1α levels either, indicating that the NLRP3 
inflammasome does not affect csIL-1α expression. We also activated the inflammasome with LPS 
and nigericin, but we were unable to reliably detect csIL-1α levels due to high levels of cell death.  
5.8. Visualising csIL-1α by immunofluorescence  
We wanted to utilise immunofluorescence (IF) to visualise csIL-1α. However, IF protocols 
typically utilise fixation of cells before antibody staining, which increases permeability and leads 
to leakage of IL-1α (as shown in Section 4.2-4.3). For this reason we stained live BMDMs with 
anti-IL-1α and a secondary antibody before fixation to try and visualise csIL-1α. Due to this live 
cell staining, we shortened the primary antibody staining to an hour at RT to preserve the viability 
of the cells, instead of the conventional ON primary antibody staining. We carried out IF with the 
same IL-1α primary antibody that we used for flow cytometry in the previous sections (BL1a-89) 
with a secondary antibody. We were able to identify potential csIL-1α staining on the BMDMs, 
which appeared as halo-like outlines of the cells (Figure 34). However, this was also present in 
Il1α-/- BMDMs, showing non-specificity of the antibody. We carried out longer dilutions of the 
antibody but found that this led to the loss of IL-1α staining in the samples. In light of this, we 
needed to find another antibody that would stain specifically for IL-1α. 
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Due to non-specificity seen in the IL-1α staining, we attempted to visualise icIL-1α with 
another primary antibody (ab7632), using the normal protocol of fixation followed by 
permeabilization prior to staining for experiments to optimise staining conditions. We also 
incorporated PI staining to determine cell viability control (Figure 35A). We were able to visualise 
icIL-1α staining (green) and the corresponding PI (orange) staining on cells that were deliberately 
permeabilised (Figure 35B). We were also able to visualise the halo-like staining previously seen 
on live stained-BMDMs (Figure 35C). These cells were negative for PI staining, indicating that 
they were not permeabilised at the time of staining.  
Figure 34: IL-1α staining of live cells produces a non-specific halo-like outline of the cell periphery. 
Immunofluorescence images showing BL1a-89 IL-1α antibody staining (green) of live WT and Il1α-/- 




Figure 35: Live cell staining with another anti-IL-1α antibody, ab7632 also shows halo-like outline. 
(A-C) IF images showing LPS-treated (1µg/ml ON) BMDMs stained with the secondary antibody and PI 
(orange) (n = 1) (A), or permeabilised BMDMs stained with an anti-IL-1α antibody (green) and PI (n = 1) 
(B), or live BMDMs stained with an anti-IL-1α antibody and PI (n = 1) (C). Primary antibody staining was 
carried out at 1:20 RT for 1h. Staining for csIL-1α was carried out on live cells with fixation after staining 
and washes. 
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To verify specificity of IL-1α staining using the ab7632 antibody, we compared WT and 
Il1α-/- BMDMs and saw that the staining patterns of WT and Il1α-/- cells were similar to each other 
for permeabilised and non-permeabilised samples (Figure 36). This showed that the staining was 
non-specific for IL-1α and further optimisation of the staining protocol was needed. We tested 
longer dilutions of this antibody (1:40, 1:50, 1:60, 1:80, 1:100 and 1:150) and also staining at 4°C 
to see if we could minimise non-specificity but we were unable to do so. 
  
Figure 36: csIL-1α IF staining at 1:20 is non-specific. 
IF images showing permeabilised or non-permeabilised LPS-treated (1µg/ml ON) WT or Il1α-/- BMDMs 
stained with an anti-IL-1α antibody (n = 1). Primary antibody staining was carried out at RT for 1h at 1:20. 
Staining for csIL-1α was carried out on live cells with fixation after staining and washes.  
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5.9. Discussion 
We have shown that csIL-1α is not an artefact and can be presented on the membrane of 
macrophages after LPS treatment. Besides TLR4, TLR2 agonists can increase csIL-1α levels and 
there is also a small increase in csIL-1α with TLR7 ligation. Broadly, TLR4 is activated by 
components of gram-negative bacteria and viruses, TLR2 by bacteria, viruses and fungi and TLR7 
by RNA viruses. This shows that a wide range of pathogens can lead to upregulation of csIL-1α, 
thus inducing an inflammatory response. However, despite treating cells with combinations of 
TLR agonists, we did not see increased csIL-1α expression compared to LPS treatment alone. This 
may indicate that the TLR4 stimulation causes a saturation of the csIL-1α being expressed on the 
cell membrane. TLR2 and TLR4 signalling share intracellular adaptor proteins including MyD88 
and TRAF6 and it may be that this signalling is at capacity with TLR4 stimulation and thus, there 
is no increase seen with additional TLR2 stimuli. 
Importantly, we find that there is de novo synthesis of icIL-1α, which is trafficked to the 
cell membrane to be presented as csIL-1α. It may be that once stimulated, icIL-1α is produced and 
it is shuttled to the cellular membrane to be expressed as csIL-1α and later shed or released to the 
extracellular space. However, it is currently not understood if secreted/released IL-1α comes from 
csIL-1α. Understanding if secreted IL-1α is derived from csIL-1α or icIL-1α may provide insight 
on the function of csIL-1α and also reveal a mechanism for IL-1α release. csIL-1α is in its precursor 
form and this has less activity than cleaved, mature IL-1α. If csIL-1α is the precursor to secreted 
IL-1α, it may point towards csIL-1α having a role on the membrane to initiate a low level of 
inflammation, which can later be cleaved to the mature form and released from the cell surface to 
lead to more potent IL-1α signalling. If csIL-1α and secreted IL-1α are produced separately and 
both are derived from icIL-1α, it may be that the function of csIL-1α is stimulating and activating 
other neighbouring cell types to lead to a local inflammatory response. 
Dexamethasone has been reported to decrease IL-1α levels in general and we also showed 
that it decreases csIL-1α levels, supporting that csIL-1α is synthesised de novo. However, this may 
be due to increased cell death as a result of dexamethasone treatment thus leading to a decreased 
number of cells in the sample and a lower level of csIL-1α detected. As all our csIL-1α experiments 
were carried out with a live/dead gate, we were able to review our data and we did not see any 
increase in cell death with dexamethasone treatment. 
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We have shown that csIL-1α on BMDMs can be cleaved by thrombin, a key enzyme in 
haemostasis that is required for coagulation. This confirms that IL-1α on the membrane is in its 
precursor full length-form, which was previously postulated by Kurt-Jones et al. (1985). We also 
detected cleaved IL-1α in the supernatant of thrombin-treated cells and this, when incubated with 
murine fibroblasts, led to the secretion of IL-6 by the fibroblasts, indicating that the cleaved csIL-
1α has bioactivity.  
Most commercial antibodies against IL-1α detect the mature 17kDa C-terminal cytokine 
region. Thus, as csIL-1α was no longer detected on the cells after incubation with thrombin, the 
C-terminal portion of IL-1α must be cleaved off into the supernatant. This indicates that IL-1α is 
bound to the membrane through its N terminus (Figure 37).  
 We found that there was a trend towards csIL-1α levels dropping after the removal of LPS 
from the media. This may indicate that constant LPS stimulation is needed to maintain csIL-1α 
levels, perhaps for the shuttling of icIL-1α to the cell surface. This may also hint at a quick response 
mechanism to activate other immune cell types, which can quickly be shut off when the stimulus 
is no longer present. As csIL-1α is in its precursor form, which is less active than mature IL-1α, it 
is likely that csIL-1α is not present to provoke a large-scale response that could damage tissues, 
but more of a rapid-response, local inflammatory environment.  
 It has been reported by Fettelschoss et al. (2011) that csIL-1α levels on human monocytes 
peaked after 6 hours of LPS stimulation, and that the conventional LPS preparation led to higher 
csIL-1α expression compared to ultra-pure LPS and this is consistent with our findings (Figure 
24A). In addition, Fettelschoss et al. showed that IL-1α secretion from human monocytes began 
Figure 37: Schematic diagram depicting hypothesised orientation of csIL-1α tethering.  







only after 12 hours of LPS stimulation. This indicates csIL-1α expression precedes release into the 
extracellular matrix, potentially hinting at csIL-1α being the precursor of secreted IL-1α. However, 
Fettelschoss et al. also used cell-surface protein biotinylation to distinguish biotinylated csIL-1α 
from other released IL-1α from LPS-treated BMDCs. As they did not detect biotinylated IL-1α in 
the supernatant, but did detect unbiotinylated IL-1α, they concluded that secreted IL-1α was not 
derived from csIL-1α, but rather released from intracellular sources (Fettelschoss et al., 2011).  
Caspase-1 (Keller et al., 2008) and caspase-11 (Wiggins et al., 2019) have been implicated 
in IL-1α release and secretion but we did not see a large difference in csIL-1α levels in these knock 
out BMDMs, also suggesting that secreted IL-1α may not be derived from csIL-1α. Together, this 
suggests that icIL-1α is the precursor of both csIL-1α and secreted IL-1α therefore showing a 
divergence of secreted IL-1α from csIL-1α (Figure 38). 
A limitation for this chapter is that a power calculation can be carried out to improve the 
analysis of this data. This calculation will allow an estimate of how many n numbers are required 











 We were not successful in staining and visualising csIL-1α and this was likely due to a 
combination antibody non-specificity and csIL-1α levels below the limit of detection by 
microscopy. In order to achieve specific staining, we would have to use an antibody dilution that 
would not allow detection of the small amount of csIL-1α present. csIL-1α immunofluorescence 
visualisation had been previously reported on murine hepatocellular carcinoma cells (Lin et al., 
2016), but these were done on fixed cells, verification of cellular integrity was not provided and 
Il1α-/- staining was not shown, all key to identify true IL-1α on the cell surface. It would be 
interesting to explore this further by other methods such as imaging flow cytometry, which allows 
for multiparameter flow analysis whilst simultaneously collecting each event by imaging 
(Barteneva et al., 2012). In addition, immunogold labelling can also be used to determine the 





Figure 38: Schematic diagram depicting the relationship between icIL-1α, csIL-1α and secreted IL-1α.  
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6. Investigating the mechanisms of membrane presentation of csIL-1α  
6.1. Introduction 
It has been suggested that csIL-1α is bound to the membrane through a lectin-like 
interaction, which can be displaced by mannose (Brody et al., 1989). Brody and Durum showed 
that this was mannose-specific as fucose did not decrease csIL-1α levels, and suggested that IL-1α 
can undergo glycosylation with these sugar moieties attaching IL-1α to the membrane. However, 
their protocol consisted of LPS-treated macrophages being treated with mannose, followed by 
fixation and a thymocyte proliferation assay for membrane IL-1 activity. We show shown in 
Section 4.3 that fixation of cells leads to intracellular leakage of IL-1α into the supernatant. Thus, 
it requires investigation to determine, without the use of a fixative, if csIL-1α is associated to the 
membrane through mannose. In addition, LPS stimulation can lead to IL-1β upregulation and in 
the experiments by Brody and Durum, it may not have been csIL-1α specifically causing 
thymocyte proliferation – rather fixation-induced leakage of intracellular IL-1α and IL-1β may 
have stimulated thymocyte proliferation.  
Interestingly, glycosylphosphatidylinositol (GPI) anchors, a post-translational 
modification known to tether many receptors and adhesion molecules to the cell surface, contains 
a mannose moiety within its structure (Figure 40). GPI anchors are involved in signal transduction 
and immune responses and their structure consists of a glycan core (consisting of mannose 
moieties), phospholipid tail and a phosphoethanolamine linker (Paulick and Bertozzi 2008). We 
postulate if GPI anchors may be an alternative way through which IL-1α is bound to the membrane, 
which might also explain why mannose can displace csIL-1α. GPI anchors can be associated with 
lipid rafts where the lipid moiety of the GPI anchor interacts with the lipid microdomain. Lipid 
rafts are microdomains where there is organisation of sphingolipids and cholesterol into rafts that 
can be attached to membrane proteins (Simons et al., 1997). Importantly, GPI anchors can be 
specifically cleaved by phosphoinositide phospholipase C (PI-PLC) (Lehto et al., 2002; Müller et 
al., 2012) (Figure 39). 
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There are several hypotheses suggested for csIL-1α tethering. Myristoylation of IL-1α has 
been reported to occur at the N terminus of the precursor on specific lysine residues (Lys-82 and 
Lys-83), not far from a phosphorylation site (Ser-90) (Stevenson et al., 1993). The authors have 
suggested that myristoylation at these sites may have a regulatory role on IL-1α interaction with 
the cell surface. Besides being tethered through a lectin-like interaction (Brody et al., 1989), it has 
also been hypothesised that full length IL-1α bound to the receptors in the cytosol is cycled through 
endosomal vesicles and presented on the cell surface (Beuscher et al., 1988). However, although 
Fettelschoss et al. (2011) found that there was no decrease in csIL-1α on Il1r1-/- BMDCs compared 
to WT, it has not been investigated if csIL-1α may be bound to the decoy receptor IL-1R2. Thus, 
we examined whether IL-1α is tethered to the cell surface through receptors, through a lectin-like 
interaction or via GPI anchors.  
Figure 39: The structure of a GPI anchor.  
Taken from Sigma-Aldrich. The PI-PLC cleavage site is marked. 
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6.2. RNAimax decreases both csIL-1α and IL-1α release from BMDMs 
As IL-1α can bind to IL-1R1 and IL-1R2, we used siRNA to knock-down Il1r1 and Il1r2 
expression and subsequently measured csIL-1α levels. However, we noticed that all samples 
treated with the siRNA delivery agent RNAiMAX expressed very low csIL-1α. Upon 
investigation, we found that BMDMs treated with the transfection reagent alone had reduced csIL-
1α on the membrane (Figure 40). Due to this, we did not carry out further transfections using 
RNAiMAX. The RNAiMAX transfection reagent likely utilises cationic liposomes to deliver 
siRNA to the cells, which may disrupt the lipid membrane and association of csIL-1α.   
6.3. IL-1α may be tethered to the cell surface via interaction with IL-1R2  
IL-1R2 is expressed on macrophages, monocytes, neutrophils, B cells, endothelial cells 
and keratinocytes (Colotta et al., 1996; Groves et al., 1995; Lukiw et al., 1999; McMahan et al., 
1991). Monocytes have been shown to specifically express around 1310 IL-1R2s per cell (Colotta 
et al., 1996). We measured Il1r2 mRNA in WT BMDMs and compared the levels to Il1r2-/- 
BMDMs as a control to see if WT cells expressed Il1r2. We showed that there was expression of 
Il1r2 both at baseline and with LPS stimulation (Figure 41A). We carried out this experiment using 
qPCR to detect Il1r2 levels because we were unable to obtain specific staining of IL-1R2 on the 
cell surface when comparing between WT and Il1r2-/- BMDMs despite trying various conditions 
Figure 40: Lipofectamine RNAiMAX transfection reagent decreases csIL-1α. 
Flow cytometry data showing csIL-1α expression on BMDMs treated ±RNAiMAX followed by LPS 
treatment (1µg/ml ON) (n = 5). Data represents mean ±SEM. 
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and dilutions of stain. In addition, a colleague at the lab showed that there was no decrease seen 
of IL-1α in Il1r2-/- BMDMs compared to WT (Figure 41B). 
We then investigated whether an excess of IL-1RA, which also binds to the IL-1 receptors, 
would lead to displacement of csIL-1α from LPS-treated BMDMs. We saw a significant decrease 
in csIL-1α on BMDMs that were treated with IL-1RA, indicating that csIL-1α may be tethered to 
an IL-1 receptor (Figure 42A). IL-1α treatment did not lead to any changes in csIL-1α levels. Next, 
we studied csIL-1α levels on LPS-treated Il1r2-/- and WT BMDMs and saw significantly decreased 
csIL-1α on Il1r2-/- compared to WT (Figure 42B), suggesting that csIL-1α could be tethered to IL-
1R2 on the cell membrane as this is not due to a decrease in IL-1α levels in Il1r2-/- cells. However, 
csIL-1α levels did not fall to baseline in Il1r2-/- cells, suggesting a portion of csIL-1α may be 
tethered via an alternative method. We also treated Il1r2-/- with excess IL-1RA and saw no 
significant change (Figure 42C), implying that the portion of csIL-1α displaced by IL-1RA was 
likely associated with IL-1R2.  
Figure 41: WT BMDMs express Il1r2.   
qPCR data showing Il1r2 expression of WT BMDMs ±LPS (1µg/ml ON) treatment, samples are normalised 
to ±LPS-treated Il1r2-/- BMDMs respectively (n = 2) (A). Western blot by Miss Dominika Krzyzanska (PhD 
student at Dr Murray Clarke’s lab, 2020) showing IL-1α expression in WT and Il1r2-/- BMDMs after 6h and 


































6.4. Il1r1-/- BMDMs may have decreased Il1α mRNA expression compared to WT   
To see if csIL-1α could be tethered to IL-1R1, we treated WT and Il1r1-/- BMDMs with or 
without LPS and measured csIL-1α levels (Figure 43) and saw a significant decrease in csIL-1α 
levels in the knock-out compared to WT. However, in Section 3.9, we extensively showed that 
BMDMs do not express IL-1R1, and thus it is unlikely that csIL-1α is tethered by IL-1R1.  
Figure 43: Il1r1-/- BMDMs have decreased csIL-1α levels compared to WT.  
Flow cytometry data showing csIL-1α expression on WT and Il1r1-/- BMDMs ±LPS (1µg/ml ON) treatment 
(n = 6-9). Data represents mean ±SEM, p=**<0.01. 
Figure 42: csIL-1α is tethered to IL-1R2 on BMDMs.  
(A-C) Flow cytometry data showing csIL-1α expression on LPS-treated (1µg/ml ON) WT BMDMs followed 
by IL-1RA treatment as indicated (5h) (n = 5-10) (A), or WT and Il1r2-/- BMDMs ±LPS treatment (n = 7-9) 



































































































This leads to the question, why is there a decrease in csIL-1α in the Il1r1-/- BMDMs when 
WT do not express IL-1R1? We hypothesised that this may be due to a decrease in Il1a mRNA 
levels in the knock-out cells, therefore leading to a decrease in icIL-1α and thus csIL-1α. To 
investigate this, we used WT BMDM Il1α expression as baseline and saw that Il1r1-/- BMDMs 
may have slightly less Il1α mRNA than WT (Figure 44), which could indicate that there is a defect 
in Il1a production in the knock-out cells, perhaps accounting for the difference in csIL-1α levels 
seen between WT and Il1r1-/-. However, this requires more repeats and measurement of IL-1α 
protein in Il1r1-/- to draw a firm conclusion. 
  
6.5. csIL-1α can be tethered via a glycosylphosphatidylinositol anchor 
A variety of membrane proteins are tethered to the cell surface via GPI anchors. GPI 
anchors can be specifically cleaved by PI-PLC at the position marked in Figure 40 (Low, 1989). 
Thy-1/CD90 is a cell surface protein known to be tethered by GPI anchors, and is found on EL4 
cells (Stevens et al., 1991). As a positive control we treated EL4 cells with PI-PLC and measured 
levels of Thy-1 on the cell surface. PI-PLC treatment decreased Thy-1 dramatically, while 
denatured PI-PLC and vehicle controls had no effect (Figure 45A). To tested if PI-PLC cleaved 
Figure 44: Il1r1-/- BMDMs have slightly lower levels of Il1α mRNA compared to WT.  
qPCR data showing Il1α expression in Il1r1-/- BMDMs ±LPS (1µg/ml ON) treatment. Samples are 




































membrane proteins non-specifically, we measured the levels of two macrophage surface proteins 
that are not GPI anchored. PI-PLC treatment had no effect on the level of CD45 (Figure 45B) or 
CD115 (Figure 45C), indicating that PI-PLC specifically cleaves GPI anchors. 
 
 LPS-treated BMDMs that were subsequently treated with PI-PLC showed a significant 
decrease in csIL-1α compared to vehicle control and denatured PI-PLC (Figure 46). This data 
indicates that a portion of csIL-1α can be tethered on the cell membrane by GPI anchors. As a low-
level of csIL-1α remains on LPS-treated Il1r2-/- BMDMs we wondered if this would be cleaved 
off by PI-PLC. Treatment of Il1r2-/- BMDMs with LPS followed by PI-PLC significantly 
decreased csIL-1α levels to baseline (Figure 47). This indicates that the portion of IL-1α that is not 





Figure 45: PI-PLC cleaves GPI anchors specifically  
Flow cytometry data showing Thy-1 expression on EL4 cells (n = 2) (A), or CD45 expression (n=2) (B), or 
CD115 expression (n=2) (C) on BMDMs with treatment as indicated (0.05U/ml unless otherwise stated 3h 
















































































 We tested the IL-1α levels in supernatants from LPS-treated BMDMs after treatment with 
PI-PLC and saw increased IL-1α compared to non-PI-PLC treated samples, but this was not 
significant (Figure 48A). We also tested these supernatants for IL-1α activity using murine 
fibroblasts as a bioassay, and saw a slight increase in IL-6 secretion with PI-PLC-treated samples 
Figure 46: PI-PLC treatment of Il1r2-/- BMDMs decreases csIL-1α levels to baseline. 
Flow cytometry data showing csIL-1α expression on Il1r2-/- LPS-treated (1µg/ml ON) BMDMs that were 






































Figure 47: csIL-1α is cleaved off the membrane of BMDMs by PI-PLC. 
Flow cytometry data showing csIL-1α expression on LPS-treated (1µg/ml ON) BMDMs that were washed 
and treated as indicated (3h 37°C) (n = 4-6). Data represents mean ±SEM, p=***<0.001. 
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compared to non-PI-PLC treated (Figure 48B).  The addition of an IL-1α neutralising antibody 
decreased IL-6, indicating that IL-1α in the supernatant was driving IL-6 production. Macrophages 
can secrete IL-1α when treated with LPS and this can be seen in the samples that were not treated 
with PI-PLC, leading to some bioactivity. As a positive control, murine fibroblasts treated with 
rIL-1α secreted high levels of IL-6, which was neutralised with the anti-IL-1α antibody. 
 
6.6. csIL-1α is unlikely to be tethered via a lectin-like interaction 
It has been postulated that IL-1α may be bound to the membrane via a lectin-like interaction 
(Brody et al., 1989). Lectins are proteins that bind carbohydrates or sugar moieties, and Brody and 
Durum (1989) showed that D-mannose lowered the apparent level of csIL-1α. However, they used 
mannose and fucose at 90mg/ml, which is an extraordinarily high concentration given that glucose 
is rarely used above 4.5mg/ml in cell culture. We saw that a 1h incubation of BMDMs with 
90mg/ml of mannose or fucose at 37°C resulted in very high levels of cell death compared to 
control (Figure 49). Fucose-treated samples contained 15% live cells, while mannose-treated 
samples only had 2.2% viable cells. In light of this, measurement of csIL-1α is not comparable to 
Figure 48: There is a slight increase in IL-1α detected in the supernatant after PI-PLC cleavage and this 
has some bioactivity. 
ELISA data showing IL-1α release into the supernatants from BMDMs treated ±LPS (1µg/ml ON), washed 
and treated with ±PI-PLC (0.5U/ml 3h 37°C) (n = 3-4) (A). ELISA data showing IL-6 secretion from murine 
fibroblasts incubated with supernatants from (A) treated ±anti-IL-1α neutralising antibody ±rIL-1α (n = 4) 
(B). Data represents mean ±SEM, p=***<0.001. 
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the untreated samples, with the number of live cells gated inconsistent between control and 
treatment samples. This may explain the observation by Brody and Durum (1989), where 
decreased thymocyte activity in mannose-treated samples could be due to prior leakage of icIL-1a 
out of the cells. Thus, it would be expected that samples with high cell death would have icIL-1α 
removed in the multiple washes prior to incubation with thymocytes, therefore appearing to have 
less csIL-1α activity. 
We treated cells with a lower concentration of mannose and fucose (50mg/ml) and still saw 
high levels of cell death (Figure 50A), with mannose treatment still showing the lowest cell 
survival compared to vehicle and fucose controls. We did not see any differences in csIL-1α 
expression in viable cells between the samples (Figure 50B). Again, this indicates that the 
experiments carried out by Brody and Durum (1989) were likely measuring leaked icIL-1α. 
Figure 49: There is increased BMDM cell death with mannose and fucose treatment. 
Flow cytometry plots showing LPS-treated BMDMs treated with vehicle, mannose or fucose (37°C, 1h, 
90mg/ml) (n = 1). Macrophages were stained with L/D dye and anti-IL-1α antibody and gated on live cells  




We had previously confirmed that the GPI-anchored Thy-1 was expressed at high levels 
on EL4 cells and could be cleaved off by PI-PLC (Figure 45A). Due to this, we were interested to 
see if we could compete Thy-1 off the cell surface with mannose treatment. We tested various 
concentration of mannose, but saw no changes in Thy-1 expression on EL4 cells (Figure 51), 
indicating that an excess of mannose does not lead to a general displacement of GPI-anchored 
proteins. This is in line with our previous observations with BMDMs showing that csIL-1α is 


























































Figure 50: Mannose does not lead to decrease in csIL-1α expression.  
(A-B) Flow cytometry data showing LPS-treated BMDMs treated with vehicle, mannose or fucose (37°C, 
1h, 50mg/ml) stained with L/D dye and anti-IL-1α antibody and gated on live cells to show csIL-1α 
expression (n = 1) (A), or csIL-1α quantification (n = 2) (B). Data represents mean ±SEM. 
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6.7. IL-1α is unlikely to be linked to lipid rafts on the membrane 
Emodin is a lipid raft inhibitor and has been shown to prevent the LPS-induced expression 
of pro-inflammatory cytokines like IL-1β and IL-6 (Meng et al., 2010). GPI-anchored proteins can 
also be found on lipid rafts and it is thought that there is enrichment of GPI-anchored proteins in 
these rafts, which help mediate signalling of the proteins (Wang et al., 2013). Therefore, we treated 
BMDMs with emodin and measured csIL-1α expression (Figure 52). We did not see a large 
decrease in csIL-1α levels with 3µM emodin treatment, indicating that csIL-1α anchored via GPI 








Figure 51: Thy-1, a GPI-anchored protein, is not displaced by mannose treatment. 
Flow cytometry data showing cell surface Thy-1 expression on EL4 cells after mannose treatment as 
indicated (n = 2). Data represents mean ±SEM. 
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Figure 52: The lipid raft inhibitor emodin does not decrease csIL-1α. 
Flow cytometry data showing csIL-1α expression on BMDMs after 1h of pre-treatment with 3µM 





























Il1r1-/- BMDMs showed a decrease in csIL-1α expression levels, but we had previously 
established that there is no IL-1R1 expressed on the membrane of BMDMs (Section 3.9) thus csIL-
1α cannot be tethered on the membrane to IL-1R1. We measured differences in Il1α expression 
and saw a slight decrease in the knock-outs compared to the WT. It may be that Il1r1-/- BMDMs 
display less csIL-1α on the membrane because of defective IL-1α production, but this requires 
further study to draw a conclusion. Interestingly, Fettelschoss et al. (2011) reported that IL-1α 
secretion levels between Il1r1-/- and WT cells are the same. In contrast to our data, they also 
observed that csIL-1α expression on Il1r1-/- and WT BMDCs are not different. However, this data 
was not gated specifically on viable cells, so we do not know if the IL-1α detected is specifically 
csIL-1α. To understand why there is a defect in IL-1α production in LPS-treated Il1r1-/- BMDMs, 
it would be interesting to see which part of the TLR4 signalling pathway is affected with Il1r1-/- 
cells. This can be done by measuring adaptor proteins involved in the pathway such as IRAK-1 
and TRAF-6 to see if these are decreased in the knock-out cells compared to WT. 
Fettelschoss et al. (2011) also shed IL-1R2 deliberately on Il1r1-/- BMDCs and saw no 
change in csIL-1α levels, despite confirming detection of IL-1R2 in the supernatant. We show that 
there is likely a defect in IL-1α production in Il1r1-/- cells and therefore, there is a total decrease 
of IL-1α in those cells. Therefore, if IL-1R2 was shed from Il1r1-/- cells, we would not expect to 
see much of a decrease in csIL-1α due to its already low levels of 5% and less in Il1r1-/- cells.  It 
is not known if IL-1R2 bound to csIL-1α can be shed into the supernatant, or if IL-1α bound to IL-
1R2 can be detected as a complex. Fettelschoss et al. (2011) point out that there is a divergence 
between csIL-1α and secreted IL-1α, demonstrated by their biotinylation experiments. Briefly, 
they biotinylated LPS-treated cell surface proteins and measured the amount of biotinylated IL-1α 
in the supernatant compared to unbiotinylated and they did not detect biotinylated IL-1α in the 
supernatant. One explanation for their findings may be that the biotin labelling of csIL-1α can 
hinder its interaction with IL-1R2, and/or interfere with its detection in the supernatant.  
Despite showing that there is a significant decrease of csIL-1α in Il1r2-/- BMDMs 
compared to WT, there is still a low level of csIL-1α expressed on the knock-out cells. This 
prompted us to look at alternative methods of csIL-1α tethering and we show that the portion of 
csIL-1α that is not tethered by IL-1R2 can be associated via a GPI anchor, as csIL-1α can be 
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cleaved off by PI-PLC. Despite csIL-1α levels decreasing with PI-PLC cleavage, it is unlikely that 
IL-1α is directly tethered by a GPI anchor on the cell membrane. The post-translational 
modifications for GPI anchoring are added in the ER (Chatterjee et al., 2001; Orlean et al., 2007) 
and IL-1α does not enter the ER-Golgi pathway because it lacks the signal sequence to direct it 
there. One explanation for this is that IL-1α interacts with another GPI-anchored protein that is 
removed from the membrane by PI-PLC cleavage. We see significantly lower presence of csIL-
1α in Il1r2-/- cells compared to WT and this decrease is not compensated for by GPI-associated 
csIL-1α, thus indicating that IL-1R2-tethered csIL-1α and GPI-associated csIL-1α may be formed 
from distinct pathways. A representation of csIL-1α tethering on cells is depicted in Figure 53. 
 We did not find that mannose had a specific effect on csIL-1α levels as shown by Brody 
and Durum (1989). Rather, we saw a large increase in cell death in both mannose and fucose 
treated samples, but to a lesser extent in the fucose samples. Brody and Durum also fixed their 
samples prior to detection of bioactivity of purported csIL-1α, which we have found to increase 
leakage of icIL-1α. It may be that due to an increase in cell death, icIL-1α within those cells was 
more easily washed away so that when those fixed cells are incubated with thymocytes, there 
would be less activity detected. However, we did not see any genuine differences in csIL-1α levels 
in mannose-treated samples compared to WT, indicating that csIL-1α is unlikely to be tethered to 




Figure 53: Schematic diagram depicting csIL-1α tethering on the cell membrane of macrophages. IL-1α 
production is stimulated by TLR2/4 binding to ligands and this leads to an increase in csIL-1α on the 









7. Investigating the role of IFNγ in IL-




7. Investigating the role of IFNγ in IL-1α trafficking to the plasma membrane 
7.1. Introduction 
Traditionally, macrophages can be polarised into M1 and M2 phenotypes through the 
effects of cytokines, where M1 polarisation occurs through IFNγ stimulation and M2 through IL-
4 and IL-13 (Orecchioni et al., 2019). M1 macrophages are also termed ‘classically activated’ 
macrophages and besides IFNγ, LPS has also been reported to induce this polarisation. M2 
polarisation is also known as ‘alternative activation’, where macrophages adopt an anti-
inflammatory phenotype (Stein et al., 1992) (Figure 54).  
Figure 54 describes the stimuli, cytokines secreted, markers expressed and responses 
elicited by M1 and M2 macrophages. Typically, M1 macrophages express CD16, CD86 and MHC 
II, while M2 macrophages express the mannose receptor, MHC II, c-myc and Egr2 (Jablonski et 
al., 2015; Mantovani et al., 2004). M1 macrophages can secrete pro-inflammatory cytokines such 
as TNFα, IL-1α, IL-1β, IL-6 and IL-12 (Shapouri-Moghaddam et al., 2018), and are implicated in 
anti-tumour and anti-microbial processes that lead to ROS-mediated tissue damage, enhanced TH1 
and TH17 responses (Shapouri-Moghaddam et al., 2018). M2 macrophages on the other hand, 
Figure 54: M1 and M2 macrophage subsets.  
Stimuli for polarisation, markers expressed, secretion profiles and function of the M1 and M2 macrophage 
subsets are described. Taken from Martinez and Gordon (2014). 
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secrete high levels of IL-10 and TGFβ and are involved in promoting tissue repair and TH2 
responses in parasitic infections, cancer and wound healing (Mantovani et al., 2013). In the context 
of inflammation, M1 macrophages mediate inflammatory responses, whereas M2 macrophages 
are important in the resolution of inflammation where they phagocytose damaged cells and secrete 
mediators to aid this process (Shapouri-Moghaddam et al., 2018). 
In addition, the M2 phenotype has been broken down to further categories of M2a, b and c 
(Fernando Oneissi Martinez et al., 2008) (Figure 54). Macrophages stimulated with IL-4 and IL-
13 are described to be M2a-activated, and this leads to the expression of IL-1R2 and IL-1RA 
(Fernando Oneissi Martinez et al., 2008). M2b macrophages are stimulated through TLR agonists 
and IL-1, and they can secrete both pro- and anti-inflammatory cytokines including IL-10, IL-6, 
IL-1β and TNFα (Fernando Oneissi Martinez et al., 2008). M2c macrophages are anti-
inflammatory and polarised by IL-10 and glucocorticoids, leading to release of TGFβ and IL-10 
(Fernando Oneissi Martinez et al., 2008). Interestingly, M1 macrophages can be ‘reprogrammed’ 
to M2 and vice versa, displaying plasticity of the cells depending on the signals that they are 
exposed to (Shapouri-Moghaddam et al., 2018). 
However, macrophage plasticity and a lack of strict categorisation into M1 or M2 
phenotypes have been described, and there is a discrepancy between in vivo and in vitro M1 and 
M2 classification. Orecchioni et al. (2019) reported that although there are similarities in gene 
expression between in vivo and in vitro M1 macrophages, there are many more differentially 
expressed genes, with similar findings for M2 macrophages as well, calling into question the 
classification of macrophages into M1 and M2 (Orecchioni et al., 2019). In addition, it has been 
suggested that the stimuli used by in vitro studies to give rise to M1 and M2 macrophages are not 
translatable in vivo, as there are other factors that can affect in vivo polarisation of macrophages 
such as extracellular matrix composition, balance of chemoattractants and cellular adhesion 
(Fernando O. Martinez et al., 2014). 
In disease contexts, M1 and M2 macrophages contribute to various pathologies. For 
example, in asthma M1 macrophages release nitric oxide and inflammatory cytokines, which leads 
to airway remodelling and the perpetuation of inflammation in the lung (Kurowska-Stolarska et 
al., 2009). In multiple sclerosis (MS), M1 macrophage infiltration is thought to lead to axonal loss, 
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while M2 macrophages can protect from MS through the induction of cytokines and promotion of 
T cell apoptosis (Jiang et al., 2014). 
Components of the IL-1 family are reported to be affected by the induction of the M1 or 
M2 phenotype. IFNγ, which can stimulate M1 polarisation in combination with LPS, has been 
reported to upregulate csIL-1α and secreted IL-1α in human keratinocytes (Guéniche et al., 1994). 
It has also been reported that fixed IFNγ-stimulated human macrophage-like THP-1 cells have 
increased csIL-1α and that this also produced bioactivity in WISH cells (Hou et al., 1994). In 
contrast, it has been found that IFNγ decreases IL-1β-induced IL-1α production and vice versa 
(Ghezzi et al., 1988). IFNγ and LPS stimulation has also been implicated in the upregulation of 
IL-1R1 and IL-1RAcP (Mantovani et al., 2002, 2004). In addition, IL-1R2 expression has also 
been suggested to increase with IL-4 and IL-13 stimulation, with this downregulated by IFNγ and 
LPS (Mantovani et al., 2002, 2004). IFNγ is a TH1 cytokine that is upregulated after infection, and 
can be produced by NK cells, innate lymphoid cells and T cells. IFNγ inhibition of IL-1β release 
has been found to lead to inhibition of neutrophil activation and TH17 cell differentiation 
(Eigenbrod et al., 2013). In light of this, it would be interesting to study the effects of IFNγ 




7.2. M1 polarisation of BMDMs decreases csIL-1α whereas M2 polarisation has no effect 
We were interested to see if M1 or M2 polarisation of macrophages would alter csIL-1α 
levels. IFNγ treatment of BMDMs before LPS caused a large decrease in csIL-1α levels compared 
to samples without IFNγ (Figure 55A). In contrast, IL-4 and IL-13 treatment in combination with 
LPS resulted in csIL-1α levels that were unchanged compared to control (Figure 55B).  
7.3. Low concentrations of IFNγ treatment reduces macrophage csIL-1α expression  
To explore how sensitive csIL-1α levels are to IFNγ, we stimulated LPS-treated BMDMs 
with IFNγ at various concentrations and measured csIL-1α. csIL-1α levels were significantly 
downregulated with IFNγ concentrations of 10ng/ml (Figure 56A) down to 1ng/ml (Figure 56B). 




Figure 55: M1 polarisation of BMDMs decreases csIL-1α. 
(A, B) Flow cytometry data showing csIL-1α expression on BMDMs ±IFNγ (20ng/ml) pre-treatment (4h) 
followed by ±LPS (1µg/ml ON) (50ng/ml) (n = 2-3) (A), or treated ±LPS (1µg/ml) together with ±IL-4 
(20ng/ml) and IL-13 (20ng/ml) (ON) (n = 2) (B). Data represents mean ±SEM. 
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Figure 56: IFNγ treatment of BMDMs decreases csIL-
1α levels.  
(A-C) Flow cytometry data showing csIL-1α expression 
on BMDMs when treated ±IFNγ in concentrations 
indicated, incubated together with and without LPS 
treatment (n = 1-3) (A, B), or with LPS treatment (n = 
3-9) (ON 37°C) (C). Data represents mean ±SEM, 






7.4. IFNγ does not induce shedding of csIL-1α  
We hypothesised that IFNγ might be causing shedding or internalisation of csIL-1α, 
leading to its downregulation. To test this, we treated BMDMs with LPS to establish the expression 
of csIL-1α, followed by the addition of IFNγ for 4h before assaying for csIL-1α. We saw no change 
in csIL-1α levels with IFNγ treatment (Figure 57), indicating that IFNγ is unlikely to cause csIL-
1α shedding or internalisation after it is expressed on the surface.   
7.5. csIL-1α downregulation is an IFNγ-specific effect 
To confirm the effect of IFNγ on csIL-1α levels, we treated LPS-stimulated BMDMs with 
IFNγ and an anti-IFNγ neutralising antibody. Samples treated with IFNγ alone showed decreased 
csIL-1α expression, while samples treated with IFNγ and the neutralising antibody in combination 
showed recovered csIL-1α levels (Figure 58A). IFNγR1 and IFNγR2 form a heterodimeric 
receptor where IFNγR1 is the ligand-binding chain of IFNγ and binding with IFNγR2 allows for 
formation of a signalling complex with intracellular components. To confirm that reduced csIL-
1α expression by IFNγ was due to the IFNγ signalling pathway, we treated BMDMs with IFNγ 
and an anti-IFNγR1 antibody and measured csIL-1α (Figure 58B). However, the IFNγR1 antibody 
did not increase csIL-1α levels compared to IFNγ alone at all, suggesting that the IFNγR1 antibody 
likely did not neutralise its target. This IFNγR1 antibody that was used was a binding antibody as 
opposed to a neutralising antibody, and this likely binds to a region of IFNγR1 that does not lead 
Figure 57: IFNγ treatment does not lead to shedding of csIL-1α.  
Flow cytometry data showing csIL-1α expression on BMDMs when pre-treated with LPS (1µg/ml ON) 
followed by treatment ±IFNγ (20ng/ml 4h) (n = 3).  Data represents mean ±SEM. 
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to the suppression of biological activity. As an alternative, we treated Ifnγr2-/- BMDMs with LPS 
and IFNγ, which showed no decrease in csIL-1α levels (Figure 58C), indicating that IFNγ 
signalling through its receptor does indeed lead to a decrease in csIL-1α expression. We also tested 
a JAK inhibitor (P6) that interferes with STAT signalling to see if it would recover csIL-1α levels 
on IFNγ-treated BMDMs, but P6 treatment led to increased cell death.  
 
IFNγ expression has been reported to be upregulated by IL-12 (Puddu et al., 1997), LPS 
(Fultz et al., 1993), IL-12 and IL-18 synergistically (Schindler et al., 2001) and LPS and IL-18 
synergistically (Schindler et al., 2001). This occurs through STAT4 signalling and leads to high 
levels of IFNγ secretion (Schindler et al., 2001). We were interested to see if we could stimulate 
BMDMs to secrete IFNγ, and if this increased IFNγ would have an autocrine effect on csIL-1α 
levels. To do this, we pre-treated BMDMs with IL-12 followed by LPS and measured csIL-1α. 























































































































Figure 58: IFNγ signalling through the IFNγR leads to 
decreased csIL-1α. 
(A-C) Flow cytometry data showing csIL-1α 
expression on BMDMs when treated ±IFNγ and 
±anti-IFNγ neutralising antibody +LPS (n = 3) (A), or 
±anti-IFNγR1 antibody ±LPS (1µg/ml ON) (n = 2) (B), 
or ±LPS on WT and Ifnγr2-/- BMDMs (IFNγ = 50ng/ml) 
(n = 3-6) (C). Data represents mean ±SEM, p=*<0.05, 
**<0.01, ***<0.001. 
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tested a combination of IL-12 and IL-18, but saw no difference in csIL-1α expression (Figure 
59B). In addition, we also treated BMDMs with IL-18 and/or LPS, and again did not see changes 
in csIL-1α compared to LPS alone (Figure 59C). As IL-10 inhibits IFNγ secretion (Malefyt et al., 
1991), we speculated that if a basal level of IFNγ inhibits csIL-1α expression on BMDMs, IL-10 
may prevent this. To explore this, we treated BMDMs with IL-10 and LPS, but saw no difference 
in csIL-1α compared to LPS alone (Figure 59D).  
7.6. IFNα does not decrease csIL-1α expression 
To see if type I IFNs would also decrease csIL-1α levels, we treated BMDMs with IFNα 
and measured csIL-1α levels. IFNα did not significantly alter csIL-1α expression on LPS-treated 


































































































Figure 59: csIL-1α levels on LPS-treated macrophages are not affected 
by IL-10, IL-12 or IL-18 treatment. 
(A-E) Flow cytometry data showing csIL-1α expression on BMDMs pre-
treated ±IL-12 (1h 50ng/ml) followed by ±LPS (1µg/ml ON) (n = 2) (A), or 
pre-treated ±IL-12 (10ng/ml) and IL-18 (100ng/ml) (ON) followed by 
±LPS (1µg/ml ON) (n = 2) (B), or treated ±IL-18  (100ng/ml) ±LPS (1µg/ml)  
for time as indicated (n = 2) (C), or pre-treated ±IL-10 (1h 50ng/ml) 
followed by ±LPS (1µg/ml ON) (n = 2) (E). Data represents mean ±SEM. 
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7.7. IFNγ treatment does not decrease total IL-1α levels 
We speculated that IFNγ treatment may lower csIL-1α expression by decreasing total IL-
1α levels. Indeed, Hoeksema et al. (2015) reported in a gene expression microarray that IFNγ and 
LPS treatment of BMDMs led to decreased Il1α expression compared to LPS alone. To test this, 
we carried out a western blot on BMDMs treated with LPS and IFNγ and saw that total IL-1α was 
similar with and without IFNγ treatment (Figure 61A). We also measured total IL-1α levels by 
flow cytometry and saw no difference with and without IFNγ treatment (Figure 61B). This 
indicates that IFNγ likely inhibits the specific trafficking of IL-1α to the cell surface, rather than 
inhibiting global IL-1α production.   
Figure 60: IFNα treatment does not decrease csIL-1α levels. 
Flow cytometry data showing csIL-1α expression on BMDMs treated ±LPS (1µg/ml), ±IFNα (20ng/ml) 
(ON) (n = 6). Data represents mean ±SEM.  
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Having established that IFNγ does not affect total IL-1α levels, we were interested to see 
if IFNγ would also affect IL-1α release. We treated BMDMs with LPS and IFNγ and measured 
IL-1α release from BMDMs, but saw no difference in IL-1α release without or without IFNγ 
(Figure 62A). IL-1β has been reported to be downregulated in macrophages by IFNγ treatment 
(Eigenbrod et al., 2013). We measured macrophage IL-1β secretion in response to IFNγ, and 
although there was a decrease in IL-1β secretion with IFNγ, this was not significant (Figure 62B). 
This could indicate that the secretion of IL-1α and IL-1β may be differentially regulated after IFNγ 
stimulation. 
Figure 61: Total IL-1α levels are not affected by IFNγ stimulation.  
Western blot data showing IL-1α expression in BMDMs treated ±LPS (1µg/ml), ±IFNγ (50ng/ml) (ON) 
(n = 2) (A). Flow cytometry data showing IL-1α expression in permeabilised and on non-
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Figure 62: IL-1β, but not IL-1α secretion, may be affected by IFNγ stimulation. 
(A, B) ELISA data showing IL-1α (n = 3) (A) and IL-1β (B) release when BMDMs were treated ±IFNγ 
(50ng/ml), ±LPS (1µg/ml) (ON) (n = 3). Data represents mean ±SEM. 
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7.8.  IFNγ does not decrease csIL-1α by downregulating IL-1R2 protein levels 
As IFNγ has been reported to decrease IL-1R2 expression (Mantovani et al., 2002, 2004), 
we hypothesised that IFNγ treatment might decrease csIL-1α by lowering IL-1R2 expression. We 
looked at total IL-1R2 protein expression in lysed cells by ELISA and saw that there was no change 








Figure 63: IFNγ does not affect IL-1R2 protein expression levels. 
BMDMs treated ±LPS (1µg/ml) ±IFNγ (50ng/ml) (ON) and assayed for total IL-1R2 protein expression by 
ELISA (n = 2). Data represents mean ±SEM. 
 127 
7.9.  Discussion 
We were interested to see how csIL-1α levels were affected by macrophage polarisation to 
understand the biological context of csIL-1α activity. We saw that IFNγ stimulation of 
macrophages in the presence of LPS led to significant downregulation of csIL-1α, even at pg/ml 
concentrations. However, we did not see any changes in csIL-1α expression with IL-4 and IL-13 
treatment of LPS-stimulated macrophages. This is interesting, as it would be expected that the 
more pro-inflammatory M1 macrophage would express more csIL-1α. One explanation may be 
that there is less csIL-1α expression with IFNγ/LPS stimulation because icIL-1α is being diverted 
for secretion, and so there is less IL-1α to traffic to the cell surface. However, we did not see any 
increase in secreted IL-1α or IL-1β by IFNγ and LPS-treated BMDMs compared to LPS only, 
despite their M1 phenotype. This is unexpected because it is well-accepted in the field that pro-
inflammatory cytokines including IL-1 are secreted by M1-primed macrophages (Eigenbrod et al., 
2013; Mantovani, et al., 2005; Fernando O. Martinez et al., 2014; Orecchioni et al., 2019; Schultz, 
1987; Shapouri-Moghaddam et al., 2018). In our experiments, IL-1β was if anything, slightly 
decreased with IFNγ stimulation. However, IL-1β secretion requires the activation of caspase-1 
and a two-signal activation. The macrophages were only stimulated with LPS without a secondary 
stimulus and this may explain the lack of IL-1β release.  
There is a dichotomy in the effect of IFNγ on macrophages. On one hand, IFNγ is reported 
to increase macrophage activation and lead to inflammatory cytokine secretion, increase ROS and 
NOS production and enhance TH1 responses. In contrast, inflammatory csIL-1α expression is 
prevented with IFNγ stimulation, without affecting secreted or icIL-1α levels. IFNγ is secreted by 
CD4+ TH1 cells in response to bacterial and viral pathogens and this secreted IFNγ is also important 
for a strong CD8+ response (Green et al., 2013), contributing to adaptive immunity. IL-1 
stimulation leads to an increase in IL-2 secretion, important for T cell growth and proliferation, in 
addition to increasing IL-2 receptors on the T cell membrane (Santarlasci et al., 2013b). Thus, it 
may be that when macrophages are stimulated by invading pathogens to express csIL-1α, this 
drives chemokine secretion that recruits neutrophils and monocytes, which in turn drive a local 
inflammatory environment. As inflammation progresses IL-1α is subsequently secreted, and when 
the adaptive immune system is induced, IL-1α causes T cells to proliferate and secrete IFNγ, which 
can then ‘switch off’ csIL-1α expression by macrophages and potentially other cell types that 
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express this in the local milieu, as csIL-1α is no longer needed due to the potent effects of released 
IL-1α and IL-1β that overshadow it (Figure 64).  
In addition, it may also be that macrophages express csIL-1α with the purpose of presenting 
it to T cells in order to ‘kick start’ T cell activity and proliferation. Professional APCs such as 
macrophages, DCs and B cells can internalise foreign pathogens and present the processed antigen 
on MHCII so that it is recognised by T cells and can lead to its activation. It may be that the ability 
of APCs to recognise and internalise pathogen followed by interaction with T cells make the APCs 
good candidates for IL-1α presentation on the membrane. 
Figure 64: Schematic diagram representing the suggested interaction between macrophages and T 
cells. 
Pathogenic stimuli activate macrophages (1) and increase icIL-1α levels (2), which can lead to increased 
csIL-1α (3). csIL-1α can then recruit neutrophils and monocytes. When IL-1α is secreted a few hours 
later (4), it can increase T cell proliferation (5) when the adaptive immune response is induced. T cells 
secrete IFNγ (6), which can downregulate csIL-1α expression (7) as its activity is now surpassed by 
secreted IL-1α, which can be cleaved by granzyme B secreted by T cells to yield a more active mature 










T cells also release granzyme B into the extracellular space, albeit through an unknown 
mechanism (Afonina et al., 2011), and granzyme B cleaves secreted pro-IL-1α to a more active 
mature form, and thus rendering csIL-1α expression unnecessary. Our in vitro experiments do not 
show that secreted IL-1α levels increase with IFNγ stimulation. However, it is prudent to 
remember that these experiments do not take into account macrophage and T cell interaction and 
do not reflect the interplay between the innate and adaptive immune systems. As csIL-1α is 
downregulated in this situation, we see the lack of delineation in classifying M1 macrophages as 
entirely pro-inflammatory, contributing to other reports (Fernando O. Martinez et al., 2014; 
Orecchioni et al., 2019) that the M1/M2 classification system is insufficient to describe the 
complexity and plasticity of macrophages. It would be interesting to do coculture experiments with 
macrophages and T cells to see the effect of T cell-derived IFNγ on csIL-1α. Experiments using 
Ifnγr2-/- macrophages cocultured with T cells to measure csIL-1α on macrophages to confirm that 
the effect seen is IFNγ signalling-specific would also be informative.    
We show that IFNγ downregulation of csIL-1α is prevalent even at concentration of pg/ml, 
indicating high sensitivity of macrophages to type II IFN stimulation. This effect is lost when 
IFNγR2, a component of the IFNγ signalling receptor is knocked-out. The high sensitivity of csIL-
1α to IFNγ stimulation is perhaps due to high expression of the signalling receptor on the cell 
surface, which would be interesting to examine further. Surprisingly, it has been reported that IFNγ 
increased membrane IL-1α activity on monocytes (Inamura et al., 1989). However, those 
experiments used fixation of cells and measured csIL-1α through thymocyte activity, which is not 
an accurate way to examine csIL-1α as we have shown that fixation leads to leakage of IL-1α.  
We show that the downregulation of csIL-1α is exclusive to type II IFN, as the type I IFNα 
does not lead to decreased csIL-1α levels. IFNα signals through a heterodimeric receptor 
consisting of IFNAR-1 and IFNAR-2 chains (Pogue et al., 2004), distinct from the IFNγ signalling 
receptor. IFNγ and IFNα signalling not only occurs through different receptors, but they activate 
separate targets where IFNα induces the expression of IFN-stimulated genes (ISGs), which 
contains the interferon-stimulated response element (ISRE) and this enhances transcription 
induced by IFNα in response to viral infections (Daly et al., 1993). On the other hand, IFNγ 
activates gamma interferon activation sites (GAS), which are short DNA stretches that lead to 
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enhanced transcription of IFNγ-activated genes (Decker et al., 1997). Thus, this divergence in 
signalling may account for the difference between csIL-1α expression after IFNα or IFNγ.  
 We show that IFNγ does not decrease total IL-1R2 protein levels in LPS-treated BMDMs, 
indicating that IFNγ is likely not exerting its effect on csIL-1α through inhibition of IL-1R2 
expression. Strikingly, there was IL-1R2 protein expression in samples that were not treated with 
LPS. BMDMs do not express icIL-1α in the absence of LPS but it would be interesting to see if 
csIL-1α would be expressed on the membrane after transfection of IL-1α constructs into untreated 
cells, due to the presence of IL-1R2 under these conditions.  
Not much is known about the effect of IFNγ on IL-1R2, but due to the nature of IL-1R2 as 
a decoy receptor that inhibits IL-1 signalling, it would be expected that pro-inflammatory M1 
macrophages may downregulate IL-1R2. This has been shown in monocytes where IFNγ treatment 
led to a decrease in IL-1R2 mRNA expression (Dickensheets et al., 1997). It has been reported 
that IFNγ treatment can lead to increased shedding of IL-1R2 from keratinocytes (Groves et al., 
1995). This does not align with our findings, because we do not see shedding of csIL-1α after 
IFNγ, which we propose to be tethered partially by IL-1R2. IFNγ inhibition results in nearly a total 
loss of csIL-1α expression, and thus it is likely that IFNγ is affecting both GPI-anchored and IL-
1R2-tethered forms of csIL-1α, contributing to the theory that IFNγ prevents csIL-1α trafficking. 
This can be confirmed by treating LPS-treated Il1r2-/- macrophages with IFNγ to see if csIL-1α 
levels decrease completely. 
Poly (I:C), a dsRNA that simulates viral infections, signals through TLR3 and it has been 
seen that poly (I:C) stimulation leads to IFNγ secretion (Wu et al., 2014). Previously, we did not 
see an induction of csIL-1α by Poly (I:C) (Figure 27) and it may be that IFNγ secretion was 










8 . Examination of different murine 





8. Examination of different murine and human cell types did not show csIL-1α expression 
8.1. Introduction 
At this point we have examined csIL-1α expression only on murine macrophages derived 
from the bone marrow. In the literature csIL-1α has been reported on various different cell types, 
including murine macrophages (Brody et al., 1989; Kurt-Jones et al., 1985), murine DCs 
(Fettelschoss et al., 2011), human monocytes (Conlon et al., 1987; Fettelschoss et al., 2011; 
Inamura et al., 1989; Matsushima, Taguchi, et al., 1986), growing and senescent human fibroblasts 
(Orjalo et al., 2009) and hepatocellular carcinoma cells (Lin et al., 2016). TLR agonists that lead 
to csIL-1α expression on these cells included heat killed Listeria monocytogenes (activates TLR2) 
and LPS (activates TLR4). However, most of these studies were carried out on fixed cells and 
were detecting csIL-1α indirectly via T cell proliferation. 
We were interested to see if we were able to identify csIL-1α on any other immune cell 
types. Some interesting cells to investigate would be other APCs such as BMDCs and B cells to 
see if they can also express csIL-1α on their membranes and present this to T cells and lead to 
activation. It is important to identify csIL-1α expression on other cell types as this will help us 
understand how csIL-1α behaves in diseases and normal physiology, an area that is not well studied 





8.2. csIL-1α expression on murine immune cells 
We were interested to see if other immune cell types express csIL-1α. We tested primary 
BMDCs, neutrophils, B cells and T cells and saw that there was no expression of csIL-1α with and 



















































































BMDCs Neutrophils B cells
T cells Figure 65: Primary BMDCs, neutrophils, B cells and T cells do not 
express csIL-1α.  
Flow cytometry data showing csIL-1α expression on CD11c+ 
primary BMDCs (n = 2) (A), CD11b+ Ly6G+ primary neutrophils (n = 
1) (B), B220+ primary B cells ( n = 2) (C), or on CD3+ primary T cells 
(n = 2) (D). LPS = 1µg/ml ON. Data represents mean ±SEM.  
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8.3. Tissues from LPS-injected mouse do not express csIL-1α  
We assessed csIL-1α levels on cells from various organs and tissue including adipose 
tissue, lung, spleen and peritoneal lavage after intraperitoneal injection of LPS. We did not see any 
csIL-1α expression in any of these tissues (Figure 66). This may be due to the processing of organs 
with enzymes, which can proteolytically cleave csIL-1α off the membrane, or physical disruption 
leading to disturbance of membrane proteins including csIL-1α.   
Figure 66: csIL-1α was not detected in tissues of LPS-injected mouse. 
Flow cytometry plots showing csIL-1α expression on cells from adipose tissue, lung, peritoneal lavage 
and spleen tissue from a mouse that was injected with LPS (6h, 2mg/kg) (n = 1). 
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8.4. csIL-1α is not expressed on human cells studied 
Senescent human IMR90 immortalised fibroblasts have been described to express csIL-1α, 
which is crucial to drive the SASP (Orjalo et al., 2009). Orjalo et al. (2009) showed that csIL-1α 
was indispensable for the secretion of IL-6 and IL-8, cytokines that perpetuate the SASP in 
senescence. However, the experiments did not use a permeability gate when investigating csIL-
1α. We started by confirming the specificity of our anti-IL-1α antibody by knocking down Il1α in 
both growing and senescent IMR90s and staining for IL-1α in deliberately permeabilised cells. No 
IL-1α was expressed in growing cells, but there was expression in senescent cells (Figure 67A). 
Importantly, IL-1α expression was significantly decreased in senescent cells with IL-1α-targeted 
siRNA compared to control siRNA, proving that the antibody was specific. After verifying that 
the antibody is staining specifically, we examined growing and senescent IMR90s for IL-1α and 
saw slightly more IL-1α in senescent samples compared to growing (Figure 67B).  
We then stained IMR90s with a permeability dye and measured IL-1α levels in the live and 
dead populations. This showed more IL-1α detected in the dead cell population compared to little 
IL-1α in the live population (Figure 67C). We measured csIL-1α on both growing and senescent 
cells, gated on the live cell population and saw that there was no csIL-1α expressed (Figure 67D). 
To investigate this further we deliberately permeabilised growing and senescent cells and looked 
at IL-1α expression. This showed that the growing IMR90s had very low IL-1α whereas senescent 
IMR90s had greater expression (Figure 67E). We compared IL-1α in/on permeabilised and non-
permeabilised senescent and growing cells and showed that there was no csIL-1α in either 
conditions, but there was some icIL-1α expressed in growing cells and this level was significantly 

































Figure 67: Growing and senescent human IMR90 fibroblasts do not express csIL-1α. 
Flow cytometry data showing growing and senescent IMR90s stained for IL-1α treated ±control or IL-1α siRNA 
(n = 3) (A), gated on the whole cell population without treatment (n = 4) (B), gated on live or dead cell 
populations without treatment (n = 4) (C), gated on live cells without treatment (n = 5) (D), treated with perm 
buffer and gated on dead cell population (n = 4) (E), or treated ±perm buffer (n = 3) (F). Data represents mean 
±SEM, p=*<0.05, ***<0.001. Ctrl = control. 
 
 137 
In addition, we stained primary human macrophages and monocytes for csIL-1α but we 
did not see any expression (Figure 68A-B). However, these cells were scraped off the tissue culture 
plate due to the difficulty in detaching them with accutase, despite using non-TC treated plates, a 















Figure 68: Human macrophages and monocytes do not express csIL-1α. 




csIL-1α expression has been reported on primary murine BMDCs (Fettelschoss et al., 
2011), but no permeability gate was used to discern between live and dead cell populations. We 
did not see any csIL-1α expression when we gated specifically on live BMDCs, suggesting that 
the IL-1α detected is likely false positive staining of icIL-1α. Interestingly, we also did not see any 
csIL-1α on B cells and this shows that csIL-1α expression does not seem to correspond with the 
ability of the cells to interact with T cells as professional APCs.  
We also did not see csIL-1α expressed on neutrophils and T cells. Neutrophils have been 
reported to express high levels of IL-1R2 and this has been shown to be shed with LPS treatment 
(Martin et al., 2013). Thus, it may be that we do not detect csIL-1α due to this shedding of IL-1R2 
from neutrophils. Interestingly, TLR2 expression has been reported on neutrophils but very little 
TLR4 is seen on these cells (Kurt-Jones et al., 2002), indicating that neutrophils may respond better 
to TLR2 agonists. In addition, it may be of interest to determine if there are IL-1α-IL-1R2 
complexes in the supernatant after LPS treatment on neutrophils and if so, what kind of biological 
activity these may have. Immunoprecipitation of IL-1R2 from the supernatant using magnetic 
beads can be done and subsequent analysis measuring IL-1α in this preparation can be carried out. 
This will indicate whether csIL-1α can be expressed on neutrophils and if it is shed too quickly to 
be detected via flow cytometry. IL-1R2 is not typically expressed on T cells and this may explain 
the lack of csIL-1α expression. It may also be interesting to see if non-immune cells that are 
reported to express high levels of icIL-1α such as endothelial, epithelial and mesenchymal cells 
(Berda-Haddad et al., 2011; C. A. Dinarello, 2018) can also upregulate csIL-1α.  
We stained cell suspensions from adipose tissue, lung, spleen and peritoneal lavage, but 
did not see any csIL-1α expression. Immune cells such as macrophages, B and T cells can be 
recruited to the peritoneum after LPS injection (Ray et al., 2010), and we hoped to see increased 
csIL-1α-expressing cells in the lavage. As B and T cells did not express csIL-1α in vitro, the 
question then becomes why is there no csIL-1α detected on macrophages ex vivo in the lavage 
after stimulation? It may be that because there was a strong LPS stimulation in the peritoneum, the 
recruited T cells were induced to secrete IFNγ and this downregulated csIL-1α expression on the 
local macrophages, which can be confirmed by comparing the level of IFNγ in the lavages between 
mice injected with LPS and mice that did not receive the injection. In addition, it has also been 
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shown that intraperitoneal LPS injections leads to large amounts of neutrophil cell death after 3 
hours (Miyazaki et al., 2004), and thus even if neutrophils expressed csIL-1α, this would not be 
observed in our experiments. The lack of csIL-1α on cells of the other tissues examined can be 
explained by the processing of these tissues, which may have mechanically and enzymatically led 
to the disruption of csIL-1α from the membrane as we have shown that csIL-1α is sensitive to 
proteolytic cleavage.  
We did not see any expression of csIL-1α on primary human monocytes and macrophages, 
despite csIL-1α being reported on human monocytes. However, in order to detach the human 
macrophages and monocytes from the non-TC-treated surfaces for experiments, accutase was 
surprisingly insufficient. This was unexpected because murine macrophages and monocytes were 
easily detached using the same conditions. To mitigate this, we also tried using cold EDTA, a 
calcium chelator that can lead to cell dissociation, but this was unsuccessful thus, we had to scrape 
the cells off the culture plates, which brings into question their cellular integrity and leakage of 
icIL-1α. In order to solve this problem, Teflon cell culture bags can be used as these do not allow 
for cellular adherence. A problem that we foresee with this method is that monocytes require 
adherence to surfaces for differentiation into macrophages and this would not occur in these coated 
bags therefore, differentiation on cell culture plates followed by scraping and recovery of cells in 
these bags before staining may be an option. As of now, it may be that the reason why we are not 
observing csIL-1α on human macrophages and monocytes is because of the scraping process, 
which may be breaking apart the cells and/or physically removing csIL-1α. 
Orjalo et al. (2009) reported csIL-1α on both growing and senescent cells, with high levels 
of expression on senescent cells. We did not see csIL-1α expressed on senescent IMR90 cells. We 
showed that there was no icIL-1α in growing cells, but there were high levels of icIL-1α in 
senescent cells. This may account for the false detection of icIL-1α as csIL-1α in the absence of a 
permeability stain, which was not used in the experiments by Orjalo et al. (2009). Orjalo et al 
(2009) postulate that csIL-1α is important for the secretion of IL-6 and IL-8 as part of the SASP 
and it may be that soluble IL-1α is implicated in this process instead of csIL-1α. It would be 
interesting to identify whether IL-1α is secreted from senescent cells using ELISAs. Orjalo et al 
(2009) also report that IL-1RA treatment of senescent cells led to a decrease in IL-6 and IL-8 
secretion. We have shown that IL-1RA can displace csIL-1α from the membrane however, this 
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begs the question, how can IL-1RA displace csIL-1α if we do not detect csIL-1α on the membrane? 
An explanation may be that csIL-1α is expressed and cleaved off the cell membrane immediately, 
preventing its detection on the cell surface. We have shown that IL-1α may be bound to IL-1R2 
on the cell membrane and it may be of interest to measure IL-1R2 expression on senescent cells 
and investigate if there is IL-1R2 shed from the cell surface.  
In conclusion, the biological nature of csIL-1α is not well understood and there have not 
been many studies to understand it, identifying a gap in the knowledge that we have contributed 
to filling. Despite the lack of understanding of the membrane-bound form of IL-1α specifically, 
there have been conclusions made about its importance, e.g. in senescence. There is a lack of 
experiments carried out to understand the role of csIL-1α in vivo and thus, how it can contribute 
to disease. In this project, we present important findings that elucidate the nature of csIL-1α 
tethering to the membrane, how it may be interacting with other cell types and what the role of 
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9. General Discussion  
The IL-1 super family contains potent inflammatory and anti-inflammatory cytokines 
involved in mediating innate and adaptive immune responses. IL-1α and IL-1β are the most studied 
members of this family and they are released by both immune and structural cells, causing sterile 
inflammation. IL-1 signalling causes the upregulation of adhesion molecules and inflammatory 
mediators followed by subsequent recruitment of immune cells. This leads to the secretion of 
various chemokines and even more inflammatory molecules, causing a lot of tissue damage due to 
the ROS and cytotoxic molecules released. The production of IL-1 is important and beneficial to 
the host during stress but the prolonged and sustained release of IL-1 can cause death. Indeed, 
overproduction of IL-1 is associated with conditions such as multi-organ failure, hypotension and 
shock (Pruitt et al., 1995). The damaging effects of IL-1 signalling is reflected in the plethora of 
diseases that IL-1 is involved in including RA, cancer, atherosclerosis, type I and type II diabetes, 
and inhibition of IL-1 in these conditions has been shown to lead to positive outcome (C. A. 
Dinarello et al., 2012; Lust et al., 2009; Mandrup-Poulsen et al., 2010).  
IL-1 signalling occurs through IL-1R1, resulting in the release of pro-inflammatory 
cytokines including IL-6 and TNFα, which are important in the regulation of key cellular processes 
including cell proliferation, differentiation and apoptosis. Defective IL-1 signalling through the 
knock-out of Il1r1 leads to defective leukocyte recruitment to sites of infection, with IL-1α, rather 
than IL-1β, being responsible for this (Caffrey et al., 2015). This indicates the importance of IL-1 
signalling and the need to understand it. IL-1R1 has been reported to be found on various cell types 
including macrophages, monocytes and neutrophils, and thus it has been assumed that these cells 
can respond to IL-1 stimulation. We report that macrophages do not express IL-1R1 and that 
staining cells for IL-1R1 without a cell permeability dye leads to unreliable detection due to 
antibodies binding non-specifically to dead/dying cells (Figure 15A). We also show that 
transfecting macrophages with IL-1R1 can lead to a cellular response to IL-1 (Figure 17A). IL-
1R1 signalling can lead to the induction of a large inflammatory response that causes tissue 
damage. Thus, the additional step of IL-1R1 requiring external stimuli to be upregulated is likely 
a safeguard to prevent aberrant IL-1 signalling.  
It has been reported that M1 polarisation of macrophages through IFNγ and LPS treatment 
can lead to increased IL-1R1 expression (Mantovani et al., 2002, 2004). This should be explored 
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further, because if BMDMs polarised to M1 expressed IL-1R1, this would lead to IL-1 signalling. 
Furthermore, M1 macrophages are commonly described as IL-1 producers. Thus, a reason why 
IL-1R1 requires upregulation may be because activation of the NLRP3 inflammasome within 
macrophages causes release of large amounts of IL-1β, and thus lack of IL-1R1 on macrophages 
is a way of preventing aberrant inflammation from autocrine stimulation, illustrating the exquisite 
complexity of the regulation of inflammatory responses. IL-1 receptors are also upregulated on 
neutrophils from sepsis patients (Fasano et al., 1991), contributing to the idea that IL-1R1 can be 
upregulated in times of stress and disease.  
In addition, we found that although BMDCs do not express IL-1R1, human monocytes and 
HeLa cells do, with human monocytes expressing half the amount of IL-1R1 as HeLa cells. Despite 
IL-1R1 expression, human monocytes do not respond to rIL-1, while HeLa cells do. This 
challenges the idea that only the presence of IL-1R1 is needed for IL-1 signalling. We suggest that 
there must be a threshold above which IL-1R1 is expressed in order to lead to IL-1 signalling. Due 
to this, it would be interesting to transfect THP-1 cells (a human monocytic cell line) to see if 
overexpression of IL-1R1 to similar levels as HeLa cells would lead to IL-1 signalling. 
Alternatively, an additional factor may also be required to license IL-1 signalling, such as IL-
1RAcP. 
We show in our experiments that IL-1α can be tethered to IL-1R2 on the cell surface or 
associated with a GPI-anchored protein. We see that LPS-treated Il1r2-/- BMDMs have around 
66% less csIL-1α compared to WT BMDMs, indicating that the majority of the csIL-1α is tethered 
through IL-1R2. PI-PLC can cleave the remaining csIL-1α off from LPS-treated Il1r2-/- BMDMs, 
indicating that GPI anchors are responsible for a smaller portion of csIL-1α expression. However, 
this presents a puzzle because GPI-anchored proteins undergo synthesis through the conventional 
ER and Golgi pathway, while IL-1α does not and has never been found in the Golgi. In addition, 
proteins are typically associated to GPI anchors via their C-terminus (Orlean et al., 2007), whereas 
we report that csIL-1α must be tethered through its N-terminus (Figure 37). This means that IL-1α 
cannot be directly GPI-anchored to the plasma membrane, and there must be an alternative 
explanation for csIL-1α dependency on GPI anchors. The simplest explanation is that IL-1α 
interacts with another protein that is tethered via GPI anchors. One way to investigate this would 
be to carry out RNA-seq to identify genes coding for GPI-anchored proteins that show increased 
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expression with LPS stimulation and a decrease with IFNγ treatment, patterns that we see with 
csIL-1α expression. Proximity ligation assays (PLA), which detect protein-protein interactions, 
could be carried out to confirm csIL-1α interaction with any targets identified in the 
aforementioned RNA-seq experiment. In addition, PLA assays could also be used to visualise and 
quantify IL-1R2-IL-1α interaction on the cell membrane. 
It is not understood why csIL-1α interaction with the membrane occurs through two 
alternative forms of tethering. GPI anchors tether a range of proteins that have different functions, 
including adhesion molecules, enzymes, receptors and prion proteins (Ferguson et al., 2017). In 
addition, there are free GPI anchors on the cell membrane that are not associated with proteins, 
but it is not understood what the function of these are (Ferguson et al., 2017). It may be that after 
stimulation, if all IL-1R2 on the membrane is saturated with csIL-1α but the inflammatory signal 
still persists, IL-1α can be targeted to associate with GPI anchors as a means to increase csIL-1α 
expression on the plasma membrane. We know that csIL-1α levels persist up to 48h (Figure 25B), 
but we have not formally tested what proportions of these are GPI-anchored versus IL-1R2-
tethered and if there are changes in the ratio over time. Il1r2-/- BMDMs could be stimulated with 
increasing concentrations of LPS and csIL-1α measured over time. This will indicate if csIL-1α 
tethered by GPI accumulates over time and/or increasing strength of stimuli. The samples could 
then be cleaved with PI-PLC and IL-1α in the supernatant quantified to confirm the observations 
seen, whether there is an increase in GPI-associated csIL-1α.  
We previously showed that csIL-1α could be cleaved off the macrophage by thrombin but 
not by calpain or granzyme B. Thrombin, calpain and granzyme B cleave IL-1α at slightly different 
sites, each generating products of different lengths. It may be that the conformation of csIL-1α 
bound to IL-1R2 leads to the inability of granzyme B and calpain to access their cleavage sites, 
but leaves the thrombin cleavage site unobstructed. It has been reported that IL-1R2 binding to 
pro-IL-1α prevents calpain processing of IL-1α (Zheng et al., 2013), which is in line with our 
observations. However, if csIL-1α is partially tethered by IL-1R2 and partially associated with GPI 
anchors, GPI-associated csIL-1α would be expected to be cleaved by calpain and granzyme, but 
we do not see any decrease in calpain-treated (Figure 31) or granzyme B-treated samples (Figure 
32) compared to without treatment. One explanation for this is that the interaction between csIL-
1α and the GPI-associated protein specifically inhibits calpain and granzyme B cleavage. This can 
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be explored further with more information about the potential GPI-anchored protein responsible 
for csIL-1α tethering. 
Thrombin is an enzyme involved in haemostasis that converts fibrinogen to fibrin to form 
blood clots, and has previously been shown to increase the secretion of IL-1β, IL-6 and TNFα 
(Strande et al., 2009). Interestingly, thrombin has also been shown to be a monocyte 
chemoattractant (Bar-Shavit et al., 1983) and it may be that during inflammation thrombin is 
involved in perpetuating the local inflammatory environment by inducing pro-inflammatory 
cytokine secretion, monocyte recruitment and csIL-1α cleavage from macrophages to release the 
more potent mature IL-1α. In addition, monocytes can differentiate into macrophages to express 
even more csIL-1α and this may indicate the relationship between csIL-1α and thrombin.  
We attempted to carry out knock-downs of Il1r1 and Il1r2 in BMDMs with a cationic-lipid 
transfection reagent and found that the reagent alone led to decreased levels of csIL-1α. This could 
potentially be due to the interruption of the cellular membrane in the transfection process, which 
may cause IL-1α on the cell surface to be internalised or displaced. However, it may also be that 
IL-1α tethering to the cell surface is mediated by charge, as the transfection lipids are typically 
highly positively charged (cationic). Interestingly, GPI anchors contain a phosphatidylinositol (PI) 
group that is negatively charged (Goldenberg et al., 2010) and this could be displaced by positively 
charged molecules. Indeed, it has been suggested by Pham (2006) that proteoglycans on the cell 
membrane can act as binding sites for proteins, with neutrophil proteases being eluted from the 
cell surface by the addition of positively charged molecules. To explore this, short protein 
sequences containing positively charged amino acids could be synthesised and tested to see if they 
can displace csIL-1α from the membrane. In addition, the supernatant of these samples could be 
assayed for an increase in IL-1α level as a result of treatment. The NLS of IL-1α is also a sequence 
of positively charged amino acids at the N-terminus, which allows for IL-1α import to the nucleus 
and it may be that IL-1α is interacting with PI groups on the membrane through this region.  
In conclusion, our data has contributed to the understanding of IL-1 signalling through IL-
1R1 and the characterisation of csIL-1α and factors that affect its expression, which has not been 
well-studied. Importantly, our studies have elucidated two novel ways by which csIL-1α is 
expressed on the plasma membrane and implicated IFNγ as a key factor that controls csIL-1α 
expression. We have also identified TLRs that are involved in csIL-1α upregulation and this 
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provides the foundation with which we can explore and understand the function of csIL-1α in a 
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